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INTRODUCTION 
 
Gliomas are the predominant type of primary tumor found in the central nervous 
system (CNS). These tumors are highly invasive and notoriously refractory to 
current therapies. Patients diagnosed with a malignant glioma face a dismal 
prognosis that has remained relatively unchanged in the last three decades. A 
dire need exists to discover more effective therapies. A promising novel 
approach to glioma therapy is based upon modulating molecular mechanisms 
that regulate cell types critical for tumor growth. Recent identification of cancer 
stem cells that initiate and maintain tumor growth in gliomas has prompted 
investigation into the molecular signaling pathways that regulate this unique cell 
type. The Hedgehog (Hh) signaling pathway regulates stem cells and is activated 
in several cancer types. Prompted by the role of Hh signaling in regulating neural 
stem cell self-renewal, we investigated the potential role of the pathway in glioma 
growth. To address this question, we evaluated the status of Hh signaling in 
primary gliomas. Furthermore, we tested our hypothesis that Hh signaling 
regulates glioma growth in a relevant preclinical model. 
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CHAPTER I 
 
REGULATORY MECHANISMS IN GLIOMA BIOLOGY 
 
Gliomas 
Primary gliomas account for more than 40% of tumors of the central nervous 
system (Kleihues et al 1995). World Health Organization (WHO) classification of 
gliomas is based on two factors, (i) the predominant cell type found in the tumor, 
or phenotype, and (ii) grade of malignancy (I to IV) that is assigned based on 
extent of aggressive, proliferative, and necrotic features within the tumor 
(Kleihues et al 1995).  Table 1.1 summarizes the classification of gliomas based 
on these two factors along with pathological features. For example, a glioma that 
primarily consists of cells resembling astrocytic morphology and demonstrates a 
moderate level of proliferation in the tumor could receive a WHO classification of 
a Grade II Astrocytoma.  This type of classification serves as a prognostic 
indicator and aids treatment strategies.  Grade I pilocytic astrocytomas can 
consist of diffuse cells arranged in a fibrillary pattern amidst extensive endothelial 
proliferation.  Grade II oligodendroglioma displaying the characteristic “fried-egg” 
appearance.  Grade III anaplastic astrocytoma tend to show cellular atypia and 
poorly differentiated cells.  A grade IV GBM typically contains heterogenous 
groups highly proliferative cells that are seen surrounding regions of neo-
vasculature and necrosis. In less than 5% of GBM cases, grades II or III 
astrocytomas progress to form grade IV GBM. These tumors are hence classified 
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as secondary GBM, but are molecularly and clinically distinct from primary 
GBMs.  
 
Molecular biology of gliomas 
Distinct molecular profiles differentiate gliomas from one another (Holland 2001). 
For example, a characteristic feature of oligodendrogliomas is chromosomal 
1p/19q loss-of-heterozygosity (LOH) that leads to deletion of putative tumor 
suppressor genes (Reifenberger et al 1994). Oncogenic amplifications of genes, 
such as EGFR and PDGFR-A, are a rare occurrence in oligodendrogliomas. 
However, these genes are frequently found amplified in astrocytomas. PDGFR-A 
overexpression and p53 deletion are early oncogenic events in low-grade 
astrocytomas. Further loss of Rb gene and CDK4 amplification can lead to 
anaplastic changes in astrocytomas (Mason and Cairncross 2008). Several gene 
alterations are commonly found in GBMs including EGFR and EGF ligand 
amplification, loss of chromosome 10q and mutations in the tumor suppressor 
gene PTEN. Primary GBM rarely present with a p53 mutation - a hallmark feature 
that distinguishes them from secondary GBM (Ohgaki et al 2004). Another 
important distinction between primary and secondary GBMs that has recently 
emerged is the presence of mutations in the isocitrate dehydrogenase 1 (IDH1) 
and IDH2 genes (Yan et al 2009). The mutant form of IDH1 gene is found in 
more than 70% of grades II and III astrocytomas, oligodendrogliomas, and 
secondary GBMs, and is considered to be an early tumorigenic event (Watanabe 
et al 2009). Primary GBMs rarely (5%) expressed the mutant form. This evidence 
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further reinforced the notion of disparity between primary and secondary GBM at 
a genetic and clinical level.  
 
Therapies 
Current therapies include surgical intervention followed by a regimen of 
radiotherapy and/or chemotherapy. Surgery is the first option for most gliomas, 
although pilocytic astrocytomas are the only group that is cured by surgical 
intervention alone. In the case of malignant gliomas (grades III and IV), surgical 
resection does not seem to provide any increased survival benefit for patients 
(Sanai and Berger 2008). The highly infiltrative nature of malignant gliomas 
renders surgery ineffective in removing all tumor cells. Even total resection of 
malignant gliomas, sometimes by way of a cerebral hemispherectomy (Hillier 
1954), has proven futile in preventing recurrence of disease (Lacroix et al 2001). 
Thus, surgical intervention provides limited benefits for patients, such as global 
symptomatic relief due to release of local compression at the site of the tumor 
(Pang et al 2007). Additionally, surgery allows inspection of the resected tissue 
by a pathologist to identify phenotypic features that can aid more accurate 
diagnosis and treatment strategies. 
Radiation therapy (Laperriere et al 2002) and chemotherapeutic agents 
(Kreisl 2009), such as the alkylating agent Temozolomide (TMZ), provide only 
palliative benefits that are short-lived.  Post-operative radiotherapy is commonly 
used in newly diagnosed malignant gliomas (Keime-Guibert et al 2007, 
Kristiansen et al 1981, Walker et al 1980) since it shows a small statistically 
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significant survival benefit compared with no radiotherapy alone. The survival 
benefits depend on the method and dosage of radiation. No significant survival 
benefit differences were observed between whole brain radiation and local field 
radiation (Kita et al 1989). However, increasing the dose of radiation to 60 Gy in 
30 fractions over 45 Gy in 20 fractions did provide a small improvement in 
survival for the higher dose (Bleehen and Stenning 1991), albeit at a cost of 
increased detrimental quality-of-life especially for older patients. 
The use of chemotherapeutic agents as adjuvant to radiotherapy has 
yielded the most promising results for aggressive treatment of glioblastomas thus 
far (Nieder et al 2009). For example, a recent study demonstrated that the 
combination of TMZ and radiation treatment resulted in a marginal increase in 
survival of about 3 months for patients suffering from a grade IV GBM (Stupp et 
al 2005, Stupp et al 2009). Temozolomide (Temodar/Temodol) is an oral 
alkylating agent that damages DNA and triggers death of tumor cells (Villano et 
al 2009). Some tumor cells, however, synthesize MGMT enzyme that repairs this 
type of DNA damage. Thus, tumors treated with MGMT inhibitors or that 
demonstrate epigenetic silencing of MGMT gene are more responsive to 
Temozolomide treatment (Hegi et al 2005). Conversely, presence of MGMT can 
predict poor response to Temozolomide (El-Jawahri et al 2008, Friedman et al 
1998).  
Treatment benefits against gliomas vary based on several factors. As 
illustrated in Table 1.1, grade I gliomas are generally curable with surgical 
resection, while median survival time for a patient with a grade II glioma is 
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between 10-15 years.  Grade III glioma patients have a median survival time of 
5-10 years even after aggressive treatment.  However, grade IV glioma patients 
contend with a dismal prognosis of less than 12 months from surgical resection. 
These statistics have remained relatively unchanged in the past three decades.   
Novel treatment modalities that could provide greater benefit to patients are 
actively investigated and include VEGF inhibitors such as Genentech’s 
Bevacizumab (Avastin) to inhibit new blood vessel growth (Norden et al 2008), 
EGFR inhibitors that modulate an often-overexpressed tyrosine kinase receptor 
pathway in gliomas (Karpel-Massler et al 2009), and Gliadel wafers to provide 
localized and controlled release of chemotherapeutic agents to the tumor site 
(McGirt et al 2009).  Extent of efficacy achieved by these treatments is still under 
investigation in clinical trials.  
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Table 1.1. Phenotypic, pathological and prognostic features of gliomas 
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Cancer stem cell hypothesis 
Conventionally used treatment modalities however aim to eliminate the highly 
proliferative component of the tumor mass with multiple rounds of cytotoxic 
treatments. These approaches do not take into consideration the heterogeneity 
of cell types in gliomas or the efficacy of selectively targeting specific cells with 
greater propensity for tumorigenesis and resistance (Frosina 2009).   
In recent years, an alternate view of tumorigenesis has emerged which 
incorporates concepts from stem cell biology and developmental biology 
discipline.  This paradigm, as illustrated in Figure 1.1, contrasts with the 
aforementioned stochastic model of gliomas and suggests that cells within a 
tumor are part of a hierarchy: multi-potent cancer stem cells that give rise to 
transit-amplifying progenitor cells that propagate and become differentiated 
tumor cells (Jordan et al 2006). Cancer stem cells (CSC) are characterized by 
two unique properties: (i) the ability to initiate and propagate tumor, and (ii) the 
ability to self-renew and give rise to transit-amplifying progenitors and 
differentiated tumor cells.  
  9 
Figure 2.1. Stochastic and hierarchical models of tumor growth. (A) A stochastic model 
assumes that even in a heterogenous tumor, each cell within the tumor has equal ability to 
initiate tumor formation. (B) Conversely, the hierarchical model proposes that only a small 
subpopulation of cancer stem cells possess the ability to self-renew, initiate tumor 
formation and give rise to differentiated tumor cells. 
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This CSC hypothesis provides a framework to develop new treatment paradigms. 
The implications of this framework are enormous. Theoretically, CSC possess 
the ability to initiate and maintain growth of a tumor. CSC have been found in the 
tumor core and invasive cell populations of many solid tumors (Hermann et al 
2007, Puglisi et al 2009. Empirically, CSC have been shown to express elevated 
levels of multi-drug transporter proteins that can efflux out chemotherapeutic 
agents {Donnenberg, 2005 #206). CSC also resist radiotherapy by employing 
DNA repair mechanisms more effectively (Bao et al 2006a). Therefore, CSC are 
likely candidates that escape conventional treatment modalities and contribute to 
patient relapse. Thus, it is possible that eliminating CSC from the tumor can 
achieve maximum benefit from treatment (Park et al 2009). 
The first step towards developing targeted therapy against CSC is to 
isolate these cells and study their molecular characteristics. Since these cells 
share many characteristics with embryonic and adult stem cells, their isolation 
has relied on methodologies used to isolate embryonic and adult stem cells. In 
the case of CSC from brain tumors, two primary methods have been utilized: (i) 
culturing cells in conditions favorable to the maintenance of stem cells, and (ii) 
using unique cell surface markers to sort for stem cells. Borrowing from neural 
stem cell literature, growing tumor cells in culture conditions favorable for stem 
cell maintenance, i.e. without the addition of serum and in the presence of growth 
factors, allows stem cells to cluster together as spheres and proliferate.  These 
spheres consist of multi-potent stem cells, lineage restricted progenitor cells and 
differentiated cells (Deleyrolle and Reynolds 2009, Reynolds and Weiss 1992).  
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Similarly, glioma cells cultured in stem cell medium are termed gliomaspheres 
(GS) (Ehtesham et al 2007). Prospective isolation of stem cells in this manner 
allows the cells to be maintained in culture medium for subsequent in vitro 
experiments. The second method for stem cell isolation relies on separating cells 
that express specific stem cell markers. Ideally, these markers should be 
restricted to the stem cell only and should be present on the cell surface to allow 
for magnetic or fluorescence based separation. Borrowing from the 
hematopoeitic literature, CD133 is the best-known cell surface marker that has 
been used to isolate cancer stem cell from gliomas (Singh et al 2003). CD133 
(also known as Prominin 1 or AC133) is a novel five transmembrane domain 
protein (Yin et al 1997). In seminal studies conducted by Peter Dirk’s group 
(Singh et al 2004b), putative CSC were isolated using CD133 expression from 
gliomas and medulloblastomas.  These cells demonstrated properties of tumor-
initiation, self-renewal, propagation and multipotency. CD133+ cells isolated from 
primary human gliomas xenotransplanted in immunocompromised mice initiated 
tumor formation and faithful recapitulation of patient disease. In contrast, cultured 
cell lines maintained over long passages are immortalized and lose their ability to 
faithfully recapitulate cardinal features of the disease (Lee et al 2006).  
Using these techniques to isolate putative CSC has allowed investigation 
into their behavior at a molecular level and devise treatment paradigms 
specifically targeting these cells. Two approaches that have been reported with 
success include (i) affecting CSC ability to draw nutrients from new blood vessels 
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by eliminating neo-angiogenesis (Bao et al 2006b), and (ii) terminally 
differentiating these cells to curb their tumorigenic potential (Piccirillo et al 2006).  
Rich’s group demonstrated that administration of VEGF inhibitor, Avastin, 
led to significant decrease in the development of new blood vessels affecting 
CSC viability and tumorigenic potential (Bao et al 2006b). As a corollary, 
Gilbertson and colleagues presented evidence to show that CSC preferentially 
reside near tumor blood vessels that form a supportive niche (Calabrese et al 
2007). Thus, inhibiting new blood vessel growth may be one effective measure 
for eliminating CSC. 
Vescovi’s group (Piccirillo et al 2006) presented one of the most 
compelling pieces of evidence to illustrate the efficacy of a treatment strategy 
against CSC. This strategy relied on exposing CSC to a pro-differentiating signal 
– bone morphogenetic protein (BMP). Upon exposure to BMP, CSC were 
induced to differentiate and lost their ability to initiate tumor in xenotransplanted 
mice. BMP is a signaling molecule crucial during embryonic development and 
implicated in cancer (Blanco Calvo et al 2009). The success of this strategy 
prompts investigation into other developmental signaling pathways that may also 
be required for stem cell maintenance and tumor growth.  The Hedgehog (Hh) 
signaling pathway is one such pathway. 
 
Hedgehog signaling pathway during development and disease 
The Hh pathway is a crucial cell signaling mechanism with widespread roles 
during embryogenesis. The Hh gene was first discovered by (Nusslein-Volhard 
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and Wieschaus 1980) while conducting functional gene mutation analysis in the 
Drosophila. Later, three mammalian orthologs of the Hh protein were discovered: 
Sonic hedgehog (Shh), Indian hedgehog (Ihh) and Desert hedgehog (Dhh) 
(Bitgood et al 1996, Echelard et al 1993, Ingham and McMahon 2001, Pathi et al 
2001, St-Jacques et al 1999). In the CNS, the Hh pathway regulates some of the 
critical functions of during development and tissue homeostasis, including the 
self-renewal mechanisms of quiescent stem cells, the proliferation of the external 
granule neuron precursors in the developing cerebellum in a time and position 
dependent manner, and the patterning of the ventral neural tube (Rubin and de 
Sauvage 2006).  
In the adult neurogenic regions of the mammalian brain, namely the sub-
ventricular zone (SVZ) and the sub-granular zone (SGZ), the Hh pathway has 
been demonstrated to be important in self-renewal and proliferation of precursor 
neural stem cells (Ahn and Joyner 2005, Lai et al 2003, Machold et al 2003, 
Palma et al 2005) as illustrated in Figure 1.2c. Hh regulates the B-type stem cells 
and C-type transit-amplifying cells eventually giving rise to A-type neuroblast 
cells which migrate towards the olfactory bulb following the rostral migratory 
stream. 
During late embryogenesis and early postnatal life, Hh signal  is secreted 
from Purkinje neurons in the developing cerebellum. Hh induces the proliferation 
of external granule neuron precursors (Figure 1.2b) that migrate across the 
Purkinje neuron layer and establish the internal granular layer (Dahmane and 
Ruiz i Altaba 1999, Wechsler-Reya and Scott 1999).  
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Hh signal secreted from the notochord acts as a morphogen and patterns 
the lower ventral neural tube in a distinct, gradient specific mechanism as shown 
in Figure 1.2A.  The distance separating a Hh generating cell from a receiving 
cell during this process of cell non-autonomous signaling determines the amount 
of Hh binding and subsequent activation of the pathway. The activated pathway 
induces segmental expression of specific combinations of transcription factors 
that determine cell fate throughout the neural tube. For example, in the ventral 
neural tube, the cells closest to the source of Hh signaling express NKX2.2 and 
differentiate to become p3-domain interneurons. The cells slightly further away 
from the source express Olig2 and give rise to pMN-domain motor neurons 
(Rowitch 2004). This coordinated emergence of multiple cell types in the neural 
tube is partly determined by the extent of Hh signaling. Thus, Hh signaling serves 
as a critical regulator of cell function and fate in mammalian embryonic 
development and adult tissue maintenance. 
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Figure 1.2. Roles of Hedgehog signaling in mammalian CNS. (A) Sonic hedgehog (Shh) 
signaling regulates the self-renewal properties of quiescent stem cells present in the adult 
subventricular zone that give rise to rapidly dividing transit amplifying cells and subsequently 
migrating neuroblasts. (B) During late embryogenesis and early postnatal development, 
secretion of Shh by purkinje neurons aids the proliferation of granule cell precursors in the 
external granular layer that subsequently migrate inwards to form the internal granular layer. 
(C) Shh plays a significant role in patterning the developing neural tube. Shh secreted from 
the notochord and floor plate diffuses in a gradient to determine the fate of cells at various 
domains of the ventral neural tube. p3, p2, p1, and p0 domains give rise to interneuron 
populations while pMN domain gives rise to motor neurons and oligodendrocytes. Abb. IGL 
internal granular layer, EGL, external granular layer, PL, purkinje layer, VNT, ventral neural 
tube, NC, notochord, FP, floor plate, RP, roof plate, BMP, bone morphogenetic protein, Shh, 
sonic hedgehog. 
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Hh signal transduction cascade induces the expression of several important 
genes. The full length Hh protein in the generating cell undergoes auto-cleavage 
to produce a signaling domain that is dual-lipid modified and secreted from the 
cell surface (Pepinsky et al 1998, Porter et al 1996a, Porter et al 1996b, Wendler 
et al 2006).  Secreted Hh protein binds to its 12-transmembrane receptor 
Patched (PTCH) to release its inhibition on Smoothened (SMOH), a 7-
transmembrane protein also on the cell surface. This loss of inhibition on SMOH 
induces activation of downstream signal transduction proteins and repression of 
negative regulators of the pathway, such as Suppressor of Fused (SUFU). 
Eventual activation of the GLI transcription factors initiate transcription of Hh 
gene targets including, Nmyc and CyclinD1, along with PTCH and GLI1 
themselves. The resulting increase in PTCH protein expression on the cell 
surface allows sequestration of Hh protein near the source of the signal and acts 
as a gradient regulator in a negative-feedback loop (Chen and Struhl 1996). 
Several small molecule modulators have been synthesized to act at the level of 
Smoothened to activate or inhibit the Hh pathway (Chen et al 2002a, Chen et al 
2002b, Taipale et al 2000) (see (Rubin and de Sauvage 2006) Nature Reviews 
for a summary). The best-characterized inhibitor of the pathway is Cyclopamine, 
a plant alkyloid compound that acts at the level of SMOH and is thought to 
compete for the endogenous binding site regulated by PTCH (Chen et al 2002a, 
Cooper et al 1998).  
Aberrant regulation of the Hh pathway is implicated in many disease 
states including holoprosencephaly (Chiang et al 1996, Roessler et al 1996), 
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diabetic neuropathy (Calcutt et al 2003) and many types of cancers in the body 
(Beachy et al 2004). Interestingly, both ligand-independent and ligand-dependent 
mechanisms of Hh pathway activation have been demonstrated. The pathway is 
known to play a key role in the growth of about 30% of sporadic 
medulloblastomas, a pediatric brain tumor commonly found in the posterior 
fossa. Loss-of-function mutations in PTCH (Berman et al 2002, Chidambaram et 
al 1996, Johnson et al 1996, Unden et al 1996) and SUFU (Taylor et al 2002), or 
gain-of-function mutations in SMOH (Reifenberger et al 1998) result in 
constitutive ligand-independent activation of the pathway in medulloblastoma 
cells. Ligand-dependent pathway activation has been demonstrated in lung 
(Watkins et al 2003), foregut (Berman et al 2003), pancreatic (Thayer et al 2003) 
and metastatic prostate tumors (Fan et al 2004, Karhadkar et al 2004, Sanchez 
et al 2004). Production of the ligand in the tumor cells induces pathway activity 
and proliferative response. More recently, Fred de Sauvage’s group provided 
evidence to suggest that in several epithelial cancers, ligand-dependent Hh 
pathway activity is seen in the stromal component of the tumor and not within 
tumor cells. Hh signal generated by the tumor cells serves to activate pathway 
response in the stroma that in turn secretes tumor support factors such as VEGF 
and IGF (Theunissen and de Sauvage 2009, Yauch et al 2008). Thus, aberrant 
Hh pathway activity can take many forms leading to the development of or 
supporting the growth of cancer in several tissue types. 
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Hedgehog pathway in gliomas 
Several studies have presented evidence for Hh pathway activation in a broad 
range of glioma subtypes (Bar et al 2007, Clement et al 2007, Dahmane et al 
2001, Ehtesham et al 2007, Katayam et al 2002, Sarangi et al 2009, Xu et al 
2008). Contrary to other reports however, our studies indicate that the Hh 
pathway is activated in only distinct glioma subtypes, namely grades II and III 
astrocytomas and oligodendrogliomas but not in grade IV de novo GBM 
(Ehtesham et al 2007, Sarangi et al 2009). This distinction is important to note 
when developing clinical trials based on using Hh inhibitors to treat gliomas.  
Evaluating targeted intervention of the Hh pathway in grades II and III gliomas 
will ensure that maximum therapeutic benefit is achieved in those tumor types 
where pathway activity has been shown to be involved in tumor growth. On the 
other hand, a failed clinical trial based on Hh pathway inhibition in GBM can be 
misinterpreted as a lack of therapeutic efficacy in gliomas in general.  
Moreover, although other reports demonstrated survival benefit of 
pathway inhibition in mouse models of gliomas, they suffer from several caveats. 
The earliest studies (Dahmane et al 2001, Katayam et al 2002) only provided 
suggestive evidence based on gene and protein expression that the Hh pathway 
could be activated in gliomas, but did not elaborate on the biological role of Hh 
signaling in gliomas. One recent study xenografted a GBM cell line that had been 
transduced with a lentiviral vector to suppress Smoothened expression, and 
reported increased survival that did not reach statistical significance (Clement et 
al 2007). Another study utilized a GBM cell line transfected with GLI1 siRNA prior 
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to transplantation and reported decreased tumor volume, but did not measure 
survival (Xu et al 2008). A third study demonstrated that a GBM cell line treated 
with 10 uM cyclopamine failed to engraft in athymic nude mice (Bar et al 2007). 
However, at this dose, cyclopamine also inhibits cholesterol synthesis and thus 
cell growth in culture independent of pathway status (Beachy et al 1997). These 
studies suggest that Hh signaling may regulate GBM growth, but suffer from 
several major limitations: (i) cultured cells were manipulated prior to 
transplantation, and thus it is not known whether Hh pathway inhibition in an 
established glioma would modulate growth and survival; (ii) cultured glioma cell 
lines are known to undergo genetic changes during culture, particularly in the 
presence of serum but also using stem-cell culture techniques (Lee et al 2006); 
and (iii) a single glioma cell line was assayed in each study and thus it is not 
clear to what degree these data would apply to the broader array of malignant 
gliomas. Thus, it is imperative to have a clear understanding of which specific 
glioma subtypes possess an operational Hh pathway and establish the biological 
roles of Hh signaling in glioma tumorigenesis. Chapter II in this dissertation 
explores Hh pathway activation within a broad range of gliomas (data published 
in Ehtesham et al 2007) and demonstrates the mechanism of pathway activation.  
Chapter III demonstrates the establishment of a relevant pre-clinical 
xenotransplantation mouse model for gliomas that are used for subsequent 
studies illustrated in Chapter IV to address in the biological role of Hh signaling in 
gliomas (data published in Sarangi et al 2009). Chapter V reflects on the 
implications of our work and presents directions for future research. 
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CHAPTER II 
 
LIGAND-DEPENDENT ACTIVATION OF THE HEDGEHOG PATHWAY IN 
DISTINCT GLIOMA SUBTYPES 
 
Abstract 
The Hedgehog (Hh) signaling pathway regulates progenitor cell fate in 
embryogenesis and tumorigenesis of multiple organ systems. We have 
investigated the activity of this pathway in adult gliomas, and demonstrate that 
the Hh pathway is operational and activated within grades II (GII) and III (GIII), 
but not IV (GIV) gliomas. Furthermore, our studies reveal that pathway activity 
and responsiveness is confined to progenitor cells within these tumors. 
Additionally, we demonstrate that Hh signaling in glioma progenitor cells is 
ligand-dependent and provide evidence documenting the in vivo production of 
Sonic hedgehog (Shh) protein at the tumor margin. These findings suggest a 
regulatory role for the Hh pathway in progenitor cells within GII and GIII gliomas, 
and the potential clinical utility of monitoring and targeting this pathway in these 
primary brain tumors. 
 
Introduction 
Gliomas are the most common primary brain tumors and are divided into four 
clinical grades. World Health Organization (WHO) grades II–IV are intractable to 
current therapies and the 5-year survival rate is 33% (American Cancer Society, 
(2004)). Recently, progenitor or stem-like cells have been isolated from primary 
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brain tumors (Galli et al 2004, Hemmati et al 2003, Lee et al 2006, Singh et al 
2003, Singh et al 2004b), and termed ‘cancer stem cells’ (CSC) (Singh et al 
2004a). The CSC hypothesis suggests that stem cells constitute a small fraction 
of the tumor and give rise to partially or fully differentiated cell types comprising 
the majority of the tumor. The activation and operational status of signaling 
pathways in brain tumor CSC remain unknown, and their identification and 
characterization could yield critical targets for new therapeutic avenues. One 
such mechanism may be the Hedgehog (Hh) pathway, whose activity is required 
for the growth and maintenance of tumors of the cerebellum, skin, lung, foregut 
and prostate (Beachy et al 2004). The Hh pathway regulates progenitor cell 
proliferation within these tissues, and in this context, its activity has been linked 
to tumorigenesis. Prior reports concerning Hh signaling and gliomas have yielded 
conflicting results (Dahmane et al 2001, Katayam et al 2002), and thus the 
operational status of the pathway in gliomas remains to be determined.  
Prompted by a requirement for Hh signaling in the regulation of cerebral 
neural progenitor cells (Ahn and Joyner 2005, Lai et al 2003), we investigated the 
activity of this pathway in gliomas. Our studies indicate that the Hh pathway is 
activated within a significant portion of grade II (GII) and grade III (GIII) gliomas, 
but not in grade IV (GIV) de novo glioblastoma multiforme (GBM). We provide 
evidence that the pathway is activated within tumor cells that express the 
proliferation marker Ki67 and progenitor cell related proteins Bmi-1 and Olig2. In 
primary glioma cell lines, we demonstrate that Hh pathway activity is ligand-
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dependent and that pathway responsiveness can be measured under culture 
conditions that favor progenitor cell maintenance but not differentiation. 
Taken together, these mechanistic data provide evidence that the Hh 
pathway is activated in progenitor cells within GII and GIII gliomas, and support a 
role for Hh signaling in these tumors. 
 
Materials and methods 
 
Tissue procurement 
Brain tissues were obtained at Vanderbilt Medical Center in accordance with an 
institutional review board approved protocol. A portion of each tumor was sent to 
pathology for diagnoses and remaining tissue to a tumor bank for analyses. 
Primary brain tumors were phenotyped and graded as described (Kleihues et al 
1995, Kleihues et al 2002). 
 
Immunohistochemical analysis of tumors 
Immunodetection was performed with the following antibodies: PTCH-1 (1:200; 
Santa Cruz Biotechnologies, Santa Cruz, CA, USA, G19 Lot No. J2505), Shh 
(1:200; Santa Cruz Biotechnologies, H160), Ki67 (1:10; Chemicon, Temecula, 
CA, USA), Bmi-1 (1:50; Serological Corporations, Billerica, MA, USA), Olig2 
(1:250; Chemicon), GFAP (1:1000; Chemicon) and NeuN (1:500; Chemicon). 
Sequential double-antibody labeling was performed as described (Becher et al 
1998). In situ hybridization for Shh was performed as described (Oh et al 2005), 
with digoxigenin-labeled riboprobe synthesized from Shh cDNA (forward  
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5’-GCGGCACCAAGCTGGTGAAG-3’ and reverse  
5’-GGTGAGCAGCAGGCGCTCGC-3’). 
 
Western immunoblot analysis of tumors 
PTCH (G19, 1:200) or human a-actinin (1:200; Chemicon) immunoblotting in 
snap-frozen tumor samples was performed as described (Chen et al 2002a).  
 
RNA extraction, cDNA synthesis and QRT–PCR 
Total RNA was extracted from brain tissue with the RNeasy Mini Kit (QIAGEN), 
and Shh-LIGHT Z3 cells with the RNAqueous 4-PCR kit (Ambion). Genomic DNA 
was removed (RNase-Free DNase Set, QIAGEN) and purified RNA quantified 
(RiboGreen RNA Quantitation Kit, Molecular Probes). Single-stranded cDNA was 
synthesized with oligo(dT) and random hexamer primers (iScript cDNA Synthesis 
Kit, Bio-Rad). For negative controls, reverse transcriptase was omitted from the 
synthesis reaction (-RT). QRT-PCR was performed in triplicate for each sample 
and on the corresponding -RT control with SYBR Green Supermix (Bio-Rad), 
cDNA template, and primers for PTCH, GLI1, and GAPDH. For standard curves, 
QRT-PCR was performed on serial dilutions of a cDNA mixture; 40% Universal 
Human Reference RNA (Stratagene), 40% Total Brain RNA (Clontech), and 10% 
total RNA each from BT16, and BT17. PTCH, GLI1 and GAPDH quantities were 
determined according to the standard curve method (User Bulletin #2, PE 
Applied Biosystems). Calibrator cDNA (Universal Human Reference RNA, 
Stratagene) was included in every reaction, for comparisons among experiments. 
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PTCH expression levels in each tumor grade were analyzed using one-way 
ANOVA of log-transformed data, followed by post hoc comparisons to control 
samples by the least significant difference method. 
 
Primary glioma-derived cell culture  
Tumor samples were dissociated (Accutase, ICT), and purified with a 
discontinuous Percoll (Sigma) gradient (35% and 65%). For standard cultures, 
cells were plated in DMEM/F12, 10% FBS, and 1X Penicillin-Streptomycin 
(Invitrogen). For GS, cells were plated in non-tissue culture treated polystyrene 
flasks (BD-Falcon) in Neurobasal medium (Invitrogen) with B-27 supplement 
(Invitrogen), 2 µg/mL heparin (Sigma), 2 mM L-Gln (Invitrogen), 20 ng/mL LIF 
(Chemicon), 20 ng/mL EGF (ProSpec TechnoGene), 20 ng/mL FGFb (ProSpec 
TechnoGene), and 1X Penicillin-Streptomycin (Invitrogen). Cells were plated at 
densities of 3-5 x 104 viable cells/cm2. 
 
Reverse transcriptase (RT)–PCR  
cDNA was amplified with intron-spanning primers specific for nestin, Bmi-1, 
Musashi-1, Sox-2, CD133 and GAPDH (Supplementary Table 1) for 40 PCR 
cycles and visualized in 2% agarose/TAE gels stained with ethidium bromide. 
The identity of each amplification product was confirmed by sequencing. 
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Hh-signaling assays in primary glioma cell cultures 
Standard cell lines or GS were cultured in triplicate for 36–42 h either alone, with 
5 mM cyclopamine, 100 nM SANT1, 5 nM ShhNp (purified, fully lipid-modified 
Shh protein) (Taipale et al 2000) or varying doses (5–500 nM) of SAG. Confluent 
standard cell lines were cultured in Dulbecco’s modified Eagle’s medium/F12 
with 0.5% fetal bovine serum and GS in neurobasal medium with B-27 
supplement, 2 mg/ml heparin, 2mM L-Gln, 20 ng/ml LIF, 20 ng/ml EGF, and 20 
ng/ml FGFb. PTCH, GLI1 and GAPDH levels were measured by QRT–PCR as 
described above. 
 
Results 
 
Characterization of Patched protein expression in gliomas  
To identify Hh-responsive cells in gliomas, we assayed for expression of the Hh 
receptor Patched (PTCH; Figure 1). Immunohistochemical staining of 13 gliomas 
revealed scattered PTCH-positive cells within three GII oligodendrogliomas, one 
GII astrocytoma and three GIII anaplastic astrocytomas, but not in any of three 
GIV de novo GBM (Figure 2.2d–l and Supplementary Figure 2.S1A and C). Rare 
PTCH-positive cells could be seen in only one of three pilocytic astrocytomas 
(Figure 2.2a–c). Histopathological examination revealed anisokaryosis within 
PTCH-expressing cells, indicating their malignant phenotype. PTCH protein 
expression in GII and GIII gliomas was further corroborated by Western 
immunoblot (Figure 2.2m, lanes 3–6). Conversely, PTCH protein expression was 
lower in GI and GIV gliomas (Figure 2.2m, lanes 1, 2, 7 and 8). 
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Figure 2.1. Schematic of the Hh pathway and pharmacological modulators. Depicted are Hh 
pathway components and gene targets PTCH and GLI1. Also shown are small molecule 
antagonists (cyclopamine and SANT1) and agonist (SAG) that modulate SMOH activity. 
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Figure 2.2. PTCH protein expression in gliomas. (a–l) Immunostaining 
revealed PTCH expression (arrow heads) within a subset of 
neoplastic cells predominantly in GII and GIII gliomas, rarely in PA, 
and not in GBM. (m) Analysis of PTCH expression levels by 
immunoblotting and QRT–PCR (PTCH level in bottom row of table) 
demonstrated the highest levels in GII and GIII gliomas. PA, pilocytic 
astrocytoma; O, oligodendroglioma; A, astrocytoma; AA, anaplastic 
astrocytoma; GBM, glioblastoma multiforme. 
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 Figure 2.S1. PTCH protein expression in a GII oligodenroglioma 
andGIII anaplastic astrocytoma. A-D, PTCH immunostaining in frozen 
tissue sections of a GII oligodendroglioma (A and B) and a GIII 
anaplastic astrocytoma (C and D) revealed PTCH expression within a 
subset of cells (A and C). Specificity of PTCH staining is 
demonstrated by the elimination of signal following pre-incubation of 
G19 primary antibody was pre-incubated with a 5-fold excess (wt/wt) 
of blocking peptide (Santa Cruz Biotechnologies, B and D). E, 
Specificity of PTCH antibodies is further demonstrated by PTCH 
immunoblotting (H267 antibody) of immunoprecipitates (G19 
antibody) from NIH3T3 cells induced with Shh-CM (lanes 1 and 2) 
and HEK293 cells transfected with a human PTCH expression 
construct (lane 3). Note, PTCH staining for the anaplastic 
astrocytoma in C and D is also shown in paraffin section in Figure 2I. 
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The expression of PTCH within a subset of tumor cells suggests that Hh pathway 
activity may be confined to a specific population of glioma cell types. To 
characterize PTCH-expressing cells, we analysed a GII astrocytoma for 
coexpression of the proliferation marker Ki67 (Figure 2.3a and b) and the stem 
cell-related marker Bmi-1 (Figure 2.3c and d). By sequential double-antibody 
labeling, PTCH expression was detected in 23.1±0.5% of the cells (n=13 high-
powered microscopic fields; average±s.e.m.). Ki67 staining was observed only in 
PTCH-expressing cells and was coexpressed in 9.3705% of the PTCH-positive 
cells (n=8). Bmi-1 was coexpressed in 87.3±2.4% of PTCH positive cells (n=5). 
These findings suggest that proliferation is confined to PTCH-expressing cells 
with progenitor features. 
 
PTCH expression is significantly elevated within GII and GIII gliomas 
To quantify the differences observed by Western blot analysis of PTCH protein 
expression in eight gliomas of varying grades, we measured PTCH mRNA levels 
in these (Figure 2.2m) and 50 other primary brain tumors (Table 2.1). As PTCH is 
a transcriptional target of the Hh pathway (Figure 2.1), quantitative real-time–
polymerase chain reaction (QRT–PCR) measurement of PTCH mRNA levels 
provides a sensitive method for assessing the degree of Hh pathway activity in 
tumor-derived tissues and cell cultures (Berman et al 2003, Karhadkar et al 
2004). For all samples, PTCH levels were normalized to endogenous 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels and expressed as 
the fold-difference relative to a control temporal lobe sample resected from a 
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patient with epilepsy (sample 1 in Table 2.1). In contrast to control samples, the 
relative PTCH mRNA levels were 2.09±0.64 in GI (P¼0.346), 6.66±1.31 in GII 
(P=0.002), 9.26±3.09 in GIII (P=0.003) and 1.15±0.18 in GIV (P=0.808) gliomas 
(average±s.e.m.), indicating significant elevation of PTCH mRNA levels only 
within GII (n=12) and GIII (n=12) gliomas. With the exception of a 
medulloblastoma, low PTCH levels were measured in the other primary brain 
tumors (samples 56–62 in Table 2.1), and these were not included in our 
statistical analyses. 
Within GII and GIII tumors, elevated PTCH expression was detected in 
oligodendrogliomas and astrocytomas (Table 2.1 and Figure 2.4). The variability 
of PTCH levels in GII and GIII glioma samples may indicate that the Hh pathway 
is activated only in a subset of these tumors, or reflect inherent limitations of the 
sampling method (see Materials and methods section). 
Notably, 21 of the 22 GBM samples in this analysis were clinically de 
novo, and low PTCH levels in these tumors suggest the following possibilities: (i) 
the Hh pathway might be activated in de novo GBM as a consequence of PTCH 
inactivation, (ii) PTCH expression in a CSC population represents a small, and 
therefore, difficult to measure portion of GBM, or (iii) the pathway is not activated 
in de novo GBM. To test the first possibility, we measured expression of the Hh 
gene-target GLI1 (Figure 2.1) by QRT–PCR in an additional set of tissues 
(Supplementary Figure 2.S2, samples 63–77). In all 11 de novo GBM samples 
analysed, GLI1 levels were uniformly low and not elevated above those found in 
control samples. These data suggest that the Hh pathway is not activated within  
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Figure 2.3. Expression of proliferation and stem cell markers within 
PTCH-positive cells in a GII astrocytoma. Sequential doubleantibody- 
labeling demonstrated coexpression of Ki67 and Bmi-1 (red, a and c, 
respectively) with PTCH (brown, arrowheads in b and d). 
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Figure 2.4. PTCH mRNA expression in gliomas. Graphic illustration of the relative PTCH expression 
levels from samples listed in Table 1 revealed significant elevation within GII and GIII gliomas only 
(see text for statistical analyses). Also shown are PTCH levels and corresponding Shh-reporter 
activity (104-fold with maximal stimulation) in NIH3T3 cells induced with serial dilutions of Shh-CM. 
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Figure 2.S2. GLI1 mRNA expression in gliomas. Graphic illustration of relative GLI1 
expression levels (normalized to control sample 63) revealed no elevation within 11 de 
novo GBM (BT67-77). A GIII anaplastic oligodendroglioma (BT 66) was included as a 
positive control. 
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Table 2.1. Quantitative real-time PCR 
measurements of PTCH mRNA levels in 
human control brain and primary brain tumors 
Abbreviations: GBM, glioblastoma multiforme; GAPDH, 
glyceraldehyde- 3-phosphate dehydrogenase; PTCH, 
Patched; PCR, polymerase chain reaction. PTCH mRNA 
expression was normalized to that of GAPDH and is 
expressed as the fold-difference relative to control brain 
tissue sample number 1. 
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de novo GBM by loss of PTCH-mediated suppression, and that while GLI1 and 
PTCH transcripts can be detected in GBM (Dahmane et al 2001), by quantitative 
measurement their expression levels are low (Katayam et al 2002). 
 
Hh pathway responsiveness is maintained in primary progenitor cells cultured 
from GII and GIII gliomas 
To assess the operational status of the Hh pathway in GII–GIV gliomas, primary 
cell cultures were generated from freshly resected brain tumors. To obtain 
standard adherent cultures, dissociated tumor cells were plated in serum-
containing medium. For culture conditions favoring the maintenance of glioma 
progenitor cells (Galli et al 2004, Hemmati et al 2003, Lee et al 2006, Singh et al 
2003, Singh et al 2004b), dissociated cells from the same tumors were plated in 
serum-free medium supplemented with epidermal growth factor (EGF), fibroblast 
growth factor (FGF) and leukemia inhibitory factor (LIF). Under these conditions, 
spheres of cells were derived (termed glioma spheres (GS)), which expressed 
the neural precursor markers nestin, Bmi-1, Musashi-1 and Sox-2 
(Supplementary Figure 2.S3). Secondary and tertiary spheres were generated 
from dissociated GII and GIII GS plated at clonal density (data not shown). 
However, serial passage of bulk cultures did not produce expanding cell 
numbers. In contrast to the exponential growth reported for GS from GBM (Galli 
et al 2004, Lee et al 2006), the failure to generate long-term  
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Figure 2.S3. Glioma spheres (GS) express neural progenitor cell 
markers. A-B, Phase-contrast images of a standard culture (A) 
and GS (B) from a GII astrocytoma (BT20). C, GS from two 
astrocytomas (BT18 and BT20), one oligodendroglioma (BT14) 
and one anaplastic astrocytoma (BT29), four GBM (BT44, BT45, 
BT51, and BT52), and an anaplastic ependymoma (BT60) were 
characterized using RT-PCR for expression of a panel of neural 
progenitor cell markers. For each sample, products of reactions 
containing reverse transcriptase (RT, +) and those in which the 
enzyme was omitted (-) are shown. A = astrocytoma, O = 
oligodendroglioma, AA = anaplastic astrocytoma, GBM = 
glioblastoma multiforme, AE = anaplastic ependymoma.  
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Figure 2.S4. Absence of PTCH induction in glioma standard cultures. GS or 
standard cultures from a GII oligodendroglioma (BT14) were cultured in triplicate for 
36 hours either alone (control) or with 5 µM cyclopamine, 5µM tomatidine, or 5 nM 
ShhNp. The fold induction of PTCH levels observed in GS was absent in the 
corresponding standard cultures. PTCH levels in cultures treated with either 
cyclopamine or tomatidine did not differ significantly from those in corresponding 
controls. 
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GS cultures from GII and GIII gliomas may represent the requirement for 
alternative culture methods or reflect differences in growth kinetics. 
To directly assay Hh pathway activity in these primary glioma cell lines, 
PTCH and GLI1 mRNA levels were measured following culture in the presence 
or absence of purified Shh protein (ShhNp) (Taipale et al 2000), or cyclopamine, 
a specific inhibitor of Hh signaling (Figure 2.1) (Chen et al 2002a, Cooper et al 
1998). The addition of ShhNp resulted in elevations of both PTCH and GLI1 
expression in short-term GS cultures derived from GII and GIII astrocytomas and 
oligodendrogliomas, but not from any of the GBM or an anaplastic ependymoma 
(Figure 2.5a). Conversely, treatment of GS with cyclopamine did not reduce 
PTCH or GLI mRNA. Additionally, pathway responsiveness to ShhNp was absent 
in standard serum-containing primary glioma cultures (Supplementary Figure 
2.S4 and data not shown). These findings provide evidence that the Hh pathway 
is operationally intact within GII and GIII oligodendrogliomas and astrocytomas 
under culture conditions that favor progenitor cell maintenance, but not 
differentiation. 
Our results indicate that the Hh pathway is at a basal level in GII and GIII 
GS and that exogenous ligand is required to activate signaling. To further confirm 
the ability to modulate Hh signaling in GS, we sought to establish whether, once 
activated, the pathway could then be inhibited. For this purpose, additional GS 
from a GII astrocytoma and a GIII anaplastic oligodendroglioma were generated 
in the presence or absence of a Smoothened (SMOH) agonist (SAG; see Figure 
2.1) (Chen et al 2002b, Frank-Kamenetsky et al 2002). After 7  
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Figure 2.5. Characterization of Hh pathway responsiveness in glioma spheres (GS). (a) GS 
from two astrocytomas (BT18 and BT20), one oligodendroglioma (BT14), one anaplastic 
astrocytoma (BT29), four GBM (BT44, BT45, BT51 and BT52) and an anaplastic 
ependymoma (BT60) were cultured for 36 h either alone (control), with 5 mM cyclopamine 
or 5 nM ShhNp. In triplicate cultures for each cell line and culture condition, PTCH and GLI1 
levels were normalized to GAPDH and expressed relative to the untreated control GS. For 
BT14, cDNAs from triplicate samples were pooled to measure relative GLI1 values due to 
insufficient starting material. (b) GS from a GII astrocytoma (BT78), a GIII anaplastic 
oligodendroglioma (BT66) and a GBM (BT79) were generated in the presence or absence 
of SAG, removed from the corresponding parent culture and subsequently cultured either 
alone, in the presence of SANT1 or increasing doses of SAG. PTCH and GLI1 levels are 
expressed relative to GAPDH. A, astrocytoma; O, oligodendroglioma,; AO, anaplastic 
oligodendroglioma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; AE, 
anaplastic ependymoma. 
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days, GS from the corresponding parent culture were re-plated either alone in the 
presence of SANT1 (a SMOH antagonist; see Figure 2.1) (Chen et al 2002a) or 
in increasing doses of SAG. PTCH and GLI1 levels in GS derived from parent 
cultures grown in the absence of SAG were not further suppressed with SANT1 
and demonstrated dose-responsive elevations with SAG (Figure 2.5b). 
Conversely, PTCH and GLI1 levels were elevated in GS from parent cultures 
derived in the presence of SAG, and could be reduced to basal levels by SANT1 
treatment. These data demonstrate that Hh signaling in GII and GIII GS can be 
modulated by either activation or inhibition, thereby confirming the operational 
status of the pathway in these tumors.  
On the basis of our survey of 12 GII–GIV GS, we find that the ability to 
modulate a Hh pathway response in cell lines derived from oligodendroglial and 
astrocytic GII and GIII tumors, but not from GBM or an ependymoma, correlates 
well with our PTCH and GLI1 mRNA measurements in gliomas (Table 2.1, Figure 
2.4 and Supplementary Figure 2.S2). Furthermore, the inability to modulate basal 
PTCH and GLI1 levels in GBM GS with cyclopamine, SANT1, ShhNp or SAG 
(Figure 2.5a and b) suggests that the Hh pathway is unlikely to be activated or 
operationally intact in a CSC population within de novo GBM. 
 
PTCH expression is found in an Olig2-positive glial fibrillary acidic protein 
(GFAP)-negative cell population common to GII and GIII oligodendrogliomas and 
astrocytomas, but not GBM  
The heterogeneity of astrocytic and oligodendroglial tumor cells within diffuse 
gliomas is well recognized, and their classification is based on the proportion and 
spatial clustering of these two phenotypic populations. For example, as in our 
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study, tumors may be classified as astrocytoma when the two populations are 
intermingled with astrocytic predominance, and as oligoastrocytoma when the 
two populations are separated into distinct areas (Kleihues et al 1995). These 
two cell types have been shown to display mutually exclusive expression of Olig 
transcription factors and glial fibrillary acidic protein (GFAP) (Azzarelli et al 2004, 
Mokhtari et al 2005). Therefore, to evaluate in which cellular components the Hh 
pathway might be activated, we analysed PTCH expression in conjunction with 
that of Olig2 and GFAP. Within oligodendrogliomas and astrocytomas, PTCH 
expression was most readily detected within a subset of Olig2-positive and 
GFAP-negative cells (Figure 2.6a–d). However, PTCH expression was not 
confined to this population, as we also observed PTCH-positive Olig2-negative 
GFAP-negative cells within the same oligodendroglioma and astrocytoma 
samples (Figure 2.6e–h). Notably, we did not observe PTCH expression in 
GFAP-positive cells (Figure 2.6i and j). Rare Olig-2-positive GFAP-negative cells 
could be identified in de novo GBM, and these cells did not express PTCH 
(Figure 2.6k and l). These findings suggest that the Hh pathway may be activated 
within a shared population of Olig2-positive GFAP-negative cells in GII and GIII 
oligodendrogliomas and astrocytomas. 
 
Characterization of Shh expression in gliomas  
The induction of PTCH and GLI1 in GII and GIII GS by ShhNp is consistent with 
a mechanism of ligand dependent Hh pathway activation. To determine the 
source of Hh ligand in gliomas, we assayed for Sonic, Indian and Desert Hh  
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Figure 2.6. Expression of PTCH in Olig2-positive GFAP-negative cells within 
oligodendrogliomas and astrocytomas. (a–d) Immunohistochemical (a and c) 
and immunofluorescent (b and d) staining revealed the presence of PTCH 
(brown) expression within Olig2 (blue)-positive, GFAP (red)-negative cells in a 
GII oligodendroglioma (O, a and b) and a GIII anaplastic astrocytoma (AA, c 
and d). (k and l) In contrast, rare Olig2-positive GFAP-negative cells identified 
in GBM did not express PTCH. (e–h). Within GII and GIII gliomas, PTCH 
expression was also detected in Olig2-negative GFAP-negative cells. (i and j) 
The absence of GFAP (red) expression in PTCH (green)-positive cells was 
confirmed using laser scanning confocal microscopy. 
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Figure 2.S5. Expression of Shh at glioma margin. A-C, Immunostaining of a GII 
astrocytoma revealed Shh expresion within adjacent brain parenchyma in cells with 
large nuclei lightly stained with hematoxylin and pyramidal morphology (A, 
arrowheads). At higher magnification (B and C), clusters of invading tumor cells can 
be visualized in close proximity to Shh-expressing cells (arrowheads). 
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expression in GS. Shh transcript could be detected in one GIII and two GIV GS 
(Figure 2.7a), demonstrating no correlation between Shh expression and 
pathway responsiveness (Figure 2.5). These data are consistent with our 
observations that the pathway is not inhibited by cyclopamine or SANT1 
treatment and that exogenous Shh ligand or SAG are required to obtain a Hh 
response in GS (Figure 2.5). 
Corroborating these results, immunohistochemical staining for Shh in GII–
GIV gliomas revealed no discernable staining within tumor cells (Figure 2.7b–d). 
However, Shh staining was observed at the tumor margin in parenchymal cells 
with neuronal morphology adjacent to clusters of invading tumor cells 
(Supplementary Figure 2.S5) and within the tumor in cells with prominent nucleoli 
and the appearance of overrun neurons (Figure 2.7b–d). To better determine the 
cellular source of secreted ligand, we performed in situ hybridization with an Shh 
RNA probe. Signal was detected only in cells that expressed the neuronal marker 
NeuN (Figure 2.7e–g). These findings suggest that neurons may serve as an in 
vivo source of Shh ligand.  
Discussion 
Our studies define the glioma subtypes in which the Hh pathway is activated, 
namely WHO grades II and III astrocytomas and oligodendrogliomas. We have 
explored the culture conditions under which pathway modulation can be 
achieved, and demonstrate that the pathway is not operational in standard 
serum-containing cultures that induce cell differentiation, but rather in cultures 
that maintain glioma progenitor cells. Finally, we provide evidence that the Hh   
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Figure 2.7. Expression of Shh in gliomas. (a) Shh expression in GS by RT–
PCR revealed a lack of correlation with Hh-responsiveness (see Figure 5). 
For each sample, reactions containing RT (þ) and those in which the enzyme 
was omitted (_) are shown. (b and c) Immunostaining demonstrated 
expression of Shh within overrun neurons (arrow heads) in a GII 
ologodendroglioma (O) and a GIII anaplastic astrocytoma (AA). (d) Shh 
staining was not detected within GBM. (e–g) In situ hybridization confirmed 
the expression of Shh (black) message in NeuN (green)-positive neurons. 
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pathway is activated in a ligand-dependent manner, with a strict requirement for 
exogenous ligand. 
The cellular origin of gliomas is unknown, and in this context it remains to 
be determined whether the striking absence of Hh pathway activity in the 
clinically de novo GBMs we analysed indicates that many GII and GIII gliomas 
may arise from Hh-responsive cell types whereas de novo GBM do not. This 
concept is reinforced by our observation that GIV GS expressed CD133, a stem 
cell marker used to identify CSC in GBM (Bao et al 2006b, Singh et al 2003, 
Singh et al 2004b), and did not demonstrate Hh pathway modulability, whereas 
GII and GIII GS were CD133-negative and Hh-responsive (data not shown). The 
WHO classification of malignant gliomas is based on histological appearance and 
malignancy grade, with a spectrum of progression of oligodendroglioma (GII) to 
anaplastic oligodendroglioma (GIII) and of diffuse astrocytoma (GII) to anaplastic 
astrocytoma (GIII) and GBM (GIV) (Kleihues et al., 2002). Two clinical GBM 
entities have been defined, primary or de novo GBM, occurring without evidence 
of antecedent disease, and secondary GBM, resulting from progression of a 
previously diagnosed lower grade glioma. Molecular analysis supports the 
divergent evolution of de novo and secondary GBM subtypes (Maher et al 2006, 
Ohgaki et al 2004). Our data raise the possibility that the Hh pathway might be 
activated in secondary GBM. However, we were unable to address this issue as 
our series contained only one secondary GBM. Nonetheless, our determination 
that the Hh pathway is activated within GII and GIII gliomas, but not in de novo 
GBM represents an important distinction for the formulation of clinical studies to 
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investigate the use of Hh modulators as therapeutic agents. This is an important 
aspect of our findings as earlier work reporting the detection of PTCH and GLI 
transcripts in GBM tumor samples and standard glioma cell lines by 
nonquantitative methods (Dahmane et al 2001) has formed the basis for 
advocating the clinical testing of Hh inhibitors in patients with GBM (Sanai et al 
2005).  
Our demonstration of Hh-pathway responsiveness in both 
oligodendrogliomas and astrocytomas, is attributable in part, to the presence of 
PTCH expression in an Olig2-positive GFAP-negative cell population identified 
as common to classic oligodendrogliomas, pure astrocytomas and 
oligoastrocytomas (Mokhtari et al 2005). However, our identification of PTCH 
expression in Olig2-negative GFAP-negative cells suggests that Hh pathway 
activity may not be exclusive to an oligodendroglial compartment in these tumors. 
The absence of PTCH staining in GFAP-positive cells indicates that Hh pathway 
activity may not be present within later stages of astrocytic differentiation, and 
further lineage marker analysis will be required to assess its presence within 
astrocytic precursors. 
The strict requirement for Hh ligand or agonist to activate the pathway in 
cell culture, the lack of correlation between Hh ligand expression and pathway- 
responsive in GS, and the neuronal expression of Shh are consistent with a 
mechanism of ligand dependent pathway activation in GII and GIII gliomas. This 
is distinct from both the ligand-independent activation in medulloblastoma and 
the ligand-dependent mechanism identified in lung (Watkins et al 2003), foregut 
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(Berman et al 2003) and metastatic prostate (Fan et al 2004, Karhadkar et al 
2004, Sanchez et al 2004) tumors. Studies from these latter tumor types 
demonstrate endogenous Shh ligand production in tumor cells (Berman et al 
2003, Fan et al 2004, Karhadkar et al 2004, Sanchez et al 2004, Watkins et al 
2003). In contrast, our findings indicate the need for exogenous ligand to activate 
the pathway. This is an important mechanistic concept for future studies to 
determine the functional role of Hh signaling in gliomas. Hh pathway activity is 
known to contribute to the growth and maintenance of multiple tumor types 
(Beachy et al 2004). Although functional roles for Hh signaling in GII and GIII 
gliomas are yet to be determined, this study does provide relevant observations. 
For example, we report that the pathway is activated in glioma cells with 
proliferative and progenitor cell features, and that tumor cells can be visualized 
clustered around Shh expressing cells at the tumor margin. These findings 
suggest that Hh signaling may regulate glioma cell growth and invasion. 
Furthermore, given the known role of Shh signaling in initiating Olig2-mediated 
oligodendrogliogenesis during embryonic development (Ligon et al 2006), our 
data suggest an analogous function in GII and GIII gliomagenesis. As such, our 
findings point to the potential clinical utility of monitoring and targeting the Hh 
pathway in GII and GIII gliomas.  
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CHAPTER III 
 
ESTABLISHING DIRECT ORTHOTOPIC XENOGRAFT MODELS OF GLIOMAS 
 
Abstract 
A critical mechanism for studying the role of Hedgehog signaling in gliomas in 
vivo is the development of an animal model that faithfully recapitulates patient 
disease. Existing animal models rely on germ-line mutations, and heterotopic 
xenotransplantation of cell lines or primary tumor cells as secondary xenografts. 
However, these approaches are known to suffer from several limitations, 
including the inability to model the diverse genetic and phenotypic characteristics 
of gliomas, and the ectopic growth of tumors in sites that do not mirror the native 
host environment. We have utilized a direct orthotopic primary xenograft 
approach by transplanting CD133+ tumor-initiating cells from patient tumors 
samples to create models of malignant gliomas that represent patient disease.  
These xenografted tumors displayed the characteristic infiltrative and aggressive 
properties of malignant gliomas. Interestingly, low grade (grades I and II) gliomas 
demonstrated atypical features in xenografted mice, including uncharacteristically 
aggressive behavior and metastasis to lymph nodes outside the CNS. Our set of 
malignant glioma xenografts forms a panel of useful resource for pre-clinical 
studies to determine the therapeutic effects of Hh pathway inhibition on gliomas. 
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Introduction 
To test the efficacy of new treatments, it is imperative to create an animal model 
that accurately represents the patient disease. Exclusive use of in vitro assays to 
test novel compounds suffers from several limitations: (i) cultured cell lines do not 
fully recapitulate the genetic makeup and cellular heterogeneity of tumors (Lee et 
al 2006), (ii) maintaining cell lines through several passages selects for specific 
immortalized cells with the capacity to grow across multiple passages, (iii) cell 
lines do not reflect the complex 3-dimensional tumor-stroma interaction (Park et 
al 2009).  Pre-clinical testing in animal models, on the other hand, enables us to 
draw reasonable inferences in a relevant setting about the possible success of 
the treatment strategy in clinical trials. Many techniques have been utilized to 
create such glioma models including, genetically engineered mouse models 
(GEMMs) (Huse and Holland 2009), syngeneic mouse models (Mikheev et al 
2009), heterotopic subcutaneous xenografts of primary tissue (Zhou et al 2009), 
orthotopic xenografts of cultured cell lines and primary cells (Shapiro et al 1979, 
Shu et al 2008) into immunocompromised mice. Each of these methodologies 
provides certain advantages and disadvantages over the other methods. 
  Several GEMM models of gliomas are commonly used that utilize the 
mutation or deletion of critical cell cycle control and/or receptor tyrosine kinase 
(RTK) genes. For example, driving overexpression of Ras and Akt genes in 
Nestin-positive cells results in a tumor that morphologically is similar to a GBM 
(Holland 2001).  Viral expression using the RCAS system is a popular techinique 
that can induce tumorigenesis in mice by driving the overexpression of relevant 
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oncogenes, such as Ras and Akt (Holland et al 2000). A mutation in the EGFR 
gene can constitutively activate the EGF pathway. This mutant form, EGFRvIII, 
when combined with Ras gain-of-function mutation driven by a GFAP-specific 
promoter, can lead to the development of low-grade oligodendroglioma (Ding et 
al 2003). Loss of p53 expression in PTCH+/- heterozygous mice leads to sporadic 
medulloblastoma formation (Wetmore et al 2001). These GEMM models have 
the advantage of modeling certain oncogenic events in mice that replicate the 
mutations commonly seen in subsets of gliomas. The mice also present with 
greater tumor formation and mortality rates thus allowing for consistency in 
designing pre-clinical studies. However, their accuracy to represent patient 
disease is debatable since they attempt to model a combination of certain 
oncogenic events that may not fully represent the complexity of genetic changes 
present in patient disease. 
 Subcutaneous xenotransplantion of cell lines and primary tumor cells in 
immunocompromised mice has been another extensively used methodology for 
pre-clinical testing (Johnson et al 2001, Maruo et al 1990). This methodology 
generally serves as a first-line of in vivo testing mechanism for novel therapeutic 
compounds. The main advantages of using subcutaneous xenografts are the 
relative ease of designing and implementing PK/PD studies on a regular basis. 
Abundant access to cell lines and mice allows greater number of mice to be used 
and shorter periods of time-to-growth for implanted tumors. Subcutaneous 
implantation, often in the flank of mice, allows for easy quantification of palpable 
tumor volume and growth measurements. However, recent studies have 
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established the ability of tumor cells to undergo genotypic and phenotypic 
transformation in culture (De Witt Hamer et al 2008, Lee et al 2006, Pandita et al 
2004) prior to implantation. These changes do not reflect characteristics of the 
patient sample and cannot be restored in secondary xenografts (Daniel et al 
2009). Furthermore, distinct stem cell populations (Vescovi et al 2006) and 
dependency on key signaling pathways (Sasai et al 2006) can be lost in cancer 
cell cultures. Genomic profiles can be maintained to a better extent in cancer 
sphere culture, though they still fail to mirror the genotype of primary tumors (De 
Witt Hamer et al 2008, Lee et al 2006). In a secondary subcutaneous xenograft, 
since the cells are grown in an ectopic environment devoid of their natural niche 
support factors, phenotypic similarity to patient sample has been hard to maintain 
across several passages and has demonstrated limited value in predicting 
clinical efficacy (Klement et al 2000, Sharpless and Depinho 2006, Takimoto 
2001).  
To circumvent these limitations, direct orthotopic xenotransplantion of 
primary tumor cells can be utilized that negate the influences of in vitro culture, 
provide a native microenvironment, and preserve the integrity of tumor-initiating 
cell (Sarangi et al 2009, Shu et al 2008, Suggitt and Bibby 2005). This 
mechanism has been suggested as a vast improvement in predictive PK/PD 
modeling compared to subcutaneous xenografts (Daniel et al 2009, Kerbel 2003, 
Park et al 2009). This methodology preserves many of the cardinal features of 
patient tumor characteristics. Moreover, in the case of non-CNS tumor types, this 
mechanism can recapitulate distal metastasis phenotype upon surgical resection 
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of the parent transplanted tumor, thus reflecting the clinical course of patients 
who undergo surgical treatment and develop advanced metastatic disease 
(Horowitz et al 1988). Treating mice that demonstrate similar advanced disease 
phenotype can provide more relevant therapeutic efficacy data (Kerbel 2003). A 
few limitations of this methodology include: (i) depending upon the orthotopic site 
where tumor cells need to be implanted, tumor growth can be difficult to measure 
and monitor (e.g. brain), (ii) such transplantations are performed on 
immunocompromised mice to prevent rejection of foreign tissue thus limiting the 
modeling of the immunological response to tumorigenesis. 
Nevertheless, direct orthotopic xenotransplantation strategy remains one 
that closely recapitulates patient disease and maintains its characteristics upon 
serial transplantation. Moreover, one can select for specific tumor-initiating cell 
populations from gliomas, e.g. by using cell surface markers such as CD133. 
This approach has been used recently by several groups (Bao et al 2006b, 
Clement et al 2007, Sarangi et al 2009, Singh et al 2004b) to establish glioma 
xenografts in the brains of immunocompromised mice.  
 
Materials and Methods 
 
Tissue procurement  
Excess brain tumor specimens were obtained for research purposes from 
patients in accordance with a protocol approved by Vanderbilt Medical Center 
Institutional Review Board. Primary brain tumors were phenotyped and graded 
as described (Kleihues et al 1995, Kleihues et al 2002). 
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CD133 cell selection and flow cytometry 
Tumor samples were minced mechanically, dissociated with papain (Worthington 
Biochemical Corporation), and passed through a 40 µm filter. Cells were labeled 
with a CD133/1 (15 ug/ml; Miltenyi Biotec) antibody crosslinked to magnetic 
nanoparticles and subjected to immunomagnetic cell separation using the 
EasySep Magnetic Selection Kit (Stem Cell Technologies). Purity of the CD133-
enriched population was assessed by flow cytometry after labeling enriched  cells 
with CD133/2-APC (Miltenyi Biotec) antibody. Isotype-matched controls were 
included in the analysis to determine background signal levels. Gates thresholds 
were set relative to the CD133 negative-selection samples.  
 
Xenotransplantation, monitoring mice, and survival analysis 
CD133-enriched cells were transplanted into the striatum of NOD/SCID mice 
according to a protocol approved by the Vanderbilt Medical Center Institutional 
Animal Care and Use Committee. Mice were anesthetized with ketamine and 
xylazine, and securely placed on a stereotactic frame. Using aseptic surgical 
procedures, an incision was made in the scalp and a small burr-hole was drilled 
2.5 mm lateral to the bregma. CD133-enriched cells were implanted 2.5 mm into 
the right striatum using a Hamilton syringe. Mice were maintained until 
development of neurological symptoms, significant weight loss or signs of 
distress (piloerection and/or hunched posture). 
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Histology and immunohistochemistry 
Immunodetection was performed for Ki67 (1:50; Dako) and GFAP (1:500; 
Chemicon) on paraffin-embedded sections and for anti-human nuclear epitope 
(1:50; Chemicon) on frozen sections as described (Ehtesham et al 2007). 
Routine histological analysis was performed using Hematoxylin and Eosin (H&E) 
staining. 
 
Results 
 
CD133 enrichment 
We established several xenograft mouse lines using orthotopic implantation of 
CD133-enriched tumor initiating cells from primary brain tumor specimens (Table 
3.1).  The specimens used in this study were freshly resected patient glioma 
samples.  All four grades of gliomas ranging from WHO Grade I (4 specimens), 
Grade II (6 specimens), Grade III (4 specimens) and Grade IV (7 specimens) 
were represented in our study.  On the day of resection, and without passaging 
cells in culture, primary brain tumor specimens were subjected to 
immunomagnetic selection for CD133 cell surface expression using magnetic 
nanoparticle-coupled antibody.  As shown in Figure 3.1, CD133+ yield ranged 
between 2-35%.  The figure also illustrates the number of cells transplanted per 
mouse per tumor. A striking observation from our dataset suggests that there is  
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Table 3.1. Pathological features of gliomas used in our xenograft panel and details of 
implantation parameters. Table also indicates which tumors successfully engrafted in mice 
and which ones demonstrated atypical features. 
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Figure 3.1. Graphic illustration of percentage of CD133 positive cells, number of cells transplanted per 
mouse and xenograft take rate. Data is shown on a linear scale from GI to GIV tumors identified by their 
tumor number (see Table 3.1 for details). Immediate following surgical resection each patient tumor 
sample was subjected to immunomagnetic selection using magnetic nanoparticle coupled CD133/1 
antibody. Top graph plots the percentage of CD133+ cells sorted from total cell number. Depending 
upon the availability of sufficient cell numbers, a group of mice were implanted with CD133+ cells 
ranging from a 1000-100,000 cells per mouse as shown in the middle graph. The bottom graph displays 
the ratio of mice (expressed as a fraction of 1.0) that developed neurological symptoms indicating tumor 
engraftment. 
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no clear correlation between percent CD133+ cells, number of cells transplanted, 
and the grade of glioma or xenograft take rate. A fraction of CD133+ cells were 
analyzed for purity by flow cytometry using a separate fluorescent molecule 
conjugated CD133/2 antibody that recognizes a different epitope of CD133.  
Enrichment of CD133+ cells in the positive-selection ranged from 2-36% (Figure 
3.2). 
 
Direct orthotopic xenotransplantation 
CD133 enriched cells were orthotopically xenotransplanted into NOD/SCID mice. 
Once the mice started losing weight or developed neurological symptoms due to 
the tumor burden, the CD133-based magnetic selection procedure was repeated 
on harvested xenograft tumor tissue for serial passaging of CD133-enriched cells 
to the next set of mice.  In contrast to patient tissue, purity of CD133-enriched 
samples from xenograft tissue was higher, ranging from 50-80% by flow 
cytometry analysis.  For example, in the case of the PT-312-HGA tumor, we 
obtained a purity of 36.5% relatively in the CD133-positive selection from the 
patient sample. The corresponding xenograft tissue (X-312-HGA) yielded much 
greater CD133-enrichement (54.01%) in the positive selection (Figure 3.2). One 
possible explanation for this disparity could be due to the cleaner sample 
preparation obtained from a mouse brain tissue compared to the human patient 
sample which contain calcified and necrotic regions rendering the creation of a 
single cell suspension technically unfeasible. Xenograft take rate was determined 
based on the fraction of mice that developed neurological symptoms and died or  
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Figure 3.2. Purity analysis of CD133 sorted fraction from patient and xenograft tissue. A 
fraction of PT-312-HGA sorted cells were analyzed by flow cytometry using the CD133/2 
antibody. The CD133-positive fraction consisted of 36.5% pure CD133 cells that were 
completely absent in the negative fraction. The immunomagnetic selection procedure, 
however, yielded better purity of sample from xenograft tissue. Bottom panel illustrates the 
purity of the CD133 selection from the corresponding X-312-HGA sample. The CD133-positive 
fraction from the xenograft tissue contained at least 54.01% pure CD133+ cells when 
compared to the negative fraction. X-axis indicates CD133/2 mean fluorescence intensity, Y-
axis indicates side scatter profile of cells. 
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were sacrificed.  By this method, 50% of transplanted primary malignant gliomas 
(WHO grades III and IV) engrafted in 69-100% of NOD/SCID mice recipients. 
 
Faithful recapitulation of patient disease in high grade gliomas 
Consistent with corresponding tumor behavior in patients, high grade brain tumor 
xenografts faithfully recapitulated patient tumor characterisitcs.  Our high grade 
brain tumor panel consisted of four Grade III gliomas and seven Grade IV 
gliomas (Table 3.1).  Percent CD133 yield ranged from 2 – 30%.  H&E and Ki67 
staining revealed that the high grade tumor xenografts were histologically 
identical to the patient tumor samples (Figures 3.3 and 3.4).  As shown in Figure 
3.3a, invasive tumor cells expressed Ki67 abundantly and were marked by a 
human-specific antibody (HuNu). Figure 3.3b provides an example of a tumor 
developed after transplantation of a GL26 glioma cell line. The tumor develops 
into a well-circumscribed mass with sharp borders (arrow). This type of growth 
does not reflect inherent tumor characteristics of gliomas as in a patient. 
Orthotopically xenotransplanted tumors directly from the patient sample exhibited 
classic characteristics of leptomeningeal spread (Figure 3.4c), parenchymal 
invasion (Figure 3.4d), corpus callosum migration (Figure 3.4e) and seeding the 
contralateral hemisphere (Figure 3.4f).  Figure 3.5 provides additional examples 
of high grade gliomas that display phenotypically similar characteristics as patient 
gliomas. Notably, high-power magnification of xenografted tumor and patient 
tissue shows very similar morphological and histological features including, high 
MIB-index, cellular atypia and neo-vasculature.  
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Figure 3.3. Comparision of xenotranplantation results from primary and cultured cells. (a) 
Direct orthotopic xenotransplantation of primary tumor cells from malignant gliomas yields 
tumors that display many hallmark features of patient tumor characteristics, including 
infiltration into the adjacent parenchyma (inset box) and migration along white matter tracts 
of the corpus callosum (arrowheads). Both Ki67 and HuNu are used here as markers of 
xenotransplanted tumor cells. (b) On the other hand, transplantation of a cultured glioma cell 
line, GL26, forms a well-circumscribed tumor mass with sharp borders (inset box) that does 
not represent the endogenous behavior of gliomas accurately (Image courtesy of Sara 
Frappier, Graduate Student in Richard Caprioli’s Lab, Vanderbilt University). 
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Figure 3.4. Recapitulation of disease features in primary xenografts from high grade 
gliomas. The panel above illustrates hallmark features obtained from primary xenograft of a 
312-HGA (high grade astrocytoma). Both H&E and Ki67 staining show the location of the 
tumor foci in the posterior striatum (A & B). (C) shows tumor cells infiltrating and spreading 
through the leptomeninges. (D) Ki67+ tumor cells are seen invading into the parenchyma 
adjacent to the tumor injection site. (E) tumor cells can also be seen migrating along white 
matter tracts of the corpus callosum (arrowheads). (F) migrating tumor cells infiltrate areas 
on the contralateral hemisphere. (G & H) High-power magnification of H&E stained slides 
show histological similarities between xenograft and patient tissue including the presence of 
cells with atypical morphology and mitotic figures. 
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Figure 3.5. Additional high grade glioma xenograft pathology.  Malignant glioma xenografts 
consistently displayed faithful racapitulation of patient disease pathology demonstrated by 
similar histological features (H&E), proliferation capcities (Ki67) and invasion through the 
corpus callosum towards the contralateral hemisphere (inset boxes). (A) 412A-GBM and (B) 
302-AG. Abbreviations: GBM, glioblastoma multiforme, AG, anaplastic ganglioglioma. 
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The X-304-AOA tumor displayed extensively diffuse characteristics throughout 
the host brain as seen by Ki67staining (Fig 3.6) and prominent migration of tumor 
cells towards the SGZ and SVZ neurogenic niches. This infiltrative feature was 
shared in some low grade gliomas as well (Figure 3.7). Satellite cells (marked by 
Ki67 staining) were found in the SGZ of the dentate gyrus and SVZ of the 
ventricles in the X-211-O xenograft bearing brain reminiscent of transplanted 
stem cell migration to stem cell niche sites (Colmone et al 2008, Sipkins et al 
2005).   
 
Atypical features in low grade glioma xenografts 
Surprisingly, the xenografted low grade (Grade I and II) tumors consistently 
displayed an aggressive phenotype in vivo that was uncharacteristic of these 
tumors compared to their behavior in patients.  As revealed by H&E and Ki67 
staining, all five tumors that engrafted in mice displayed a propensity to migrate 
towards the meninges of the brain and spread along the outer layers of the brain 
(Figure 3.8).  Serial coronal sections of the tumor-bearing cortex revealed a 
range of histological phenotypes – non aggressive tumor foci (125-JPA, Fig 3.8) 
or an aggressive and highly malignant tumor foci (221-GG, Fig 3.8) within the 
brain parenchyma.  As demonstrated by the H&E and GFAP staining in the 221-
GG xenograft, tumor burden on the ipsilateral hemisphere near the site of 
implantation was extensive.  The contralateral hemisphere, however, was 
relatively normal with no clear evidence of tumor cells present. 
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Figure 3.6. Diffuse and infiltrative characteristics of high grade glioma. The panel above 
shows Ki67 staining in a 304-AOA glioma. Diffuse tumor cells were located all throughout 
the brain of the mouse (A). High-power magnification shows Ki67+ tumor cells on both 
hemispheres (C & D). Ki67+ tumor cells were also found in the dentate gyrus of 
hippocampus suggesting a migratory response of tumor cells toward stem cells niches (B). 
Abbreviation: AOA, anaplastic oligoastrocytoma. 
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The prominent characteristic of the low grade brain tumors from this panel was 
their ability to migrate out of the CNS and inhabit lymph nodes within the mice.  
The tumors formed large growths in the lymph nodes present in the neck of the 
affected mice above the salivary glands (Figure 3.8). The atypical growths 
consisted of tightly packed tumor cells with large nucleus and small cytoplasm as 
revealed by H&E.  Inset also shows normal lymph node structure.  Moreover, the 
cells were highly proliferative and expressed abundant Ki67 protein.  
Surprisingly, although the tumor cells expressed GFAP within the tumor foci in 
the brain, they lost GFAP expression upon metastasizing to the lymph nodes.   
 
Discussion 
Modeling gliomas accurately in mice provides an essential tool for testing novel 
therapies in a relevant setting and predicting their efficacy in clinical trials. Our 
approach to directly xenotransplant primary tumor-initiating cells in an orthotopic 
site has led to the development of several mouse models that faithfully 
recapitulate invasive growth – a cardinal feature of infiltrative gliomas. In our high 
grade glioma models, tumor cells not only invade parenchyma surrounding the 
tumor injection site (Figures 3.4 and 3.5),  but also migrate along white matter 
tracts of the corpus callosum and the meninges to infiltrate other areas of the 
brain both ipsilaterally and contralaterally. Prior to our studies, very few reports 
had demonstrated such extensive infiltrative behavior of glioma cells in a 
xenotransplantation model (Shu et al 2008). Moreover, close examination of 
xenograft tumor histology reveals phenotypic similarities with the corresponding  
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Figure 3.7. Infiltrative characteristics of low grade glioma. Diffuse and infiltrative 
characteristics were also seen in some low grade gliomas as illustrated by the Ki67 staining 
above in a 211-O xenograft. Ki67+ tumor cells can be deteced in the dentate gyrus of the 
hippocampus (A) and the subventricular zone (C & F). Tumor cells were also seen migrating 
toward the meninges of the brain (D). Abbreviations: O, oligodendroglioma. 
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Figure 3.8. Atypical features of low grade glioma xenografts. As illustrated in the panel 
above from a 125-JPA xenograft, low grade tumor cells were seen not only in the brains of 
implanted mice (A) but also in the lymph node structures of the neck (E). Tumor foci 
identified by H&E (B) also expressed proliferative (C) and astrocytic (D) markers within the 
brain. However, the metastasized tumor component showed a different phenotype. Cells 
had large nucleus with very little cytoplasm (F & G). The expressed abundant Ki67 (H) 
suggesting active cycling of cells. But GFAP staining (I) was conspicuously absent in the 
metastatic component. Panel J illustrates the location of the lymph node tumors in a image 
and diagram of the mouse anatomy. Abbreviation: JPA, juvenile pilocytic astrocytoma. 
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Figure 3.9. Aggressive features of low grade gliomas. Uncharacteristically aggressive 
features are seen in a grade II ganglioglioma (221-GG) on the ipsilateral hemisphere 
relative to the tumor injection site. H&E staining shows hypercellularity and atypical cellular 
morphology in tumor cells on the ipsilateral side (A, B, C) while the contralateral side is 
relatively normal (D, E). GFAP staining to mark tumor cells shows extensive staining in the 
ipsilateral side of the brain (F, G, H) while the corresponding contralateral side is relatively 
normal (I, J). Abbreviations: GG, ganglioglioma, IPSI, ipsilateral hemisphere , CONTRA, 
contralateral hemisphere. 
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patient tumor that is maintained across several passages in mice. This includes 
hallmark features such as cellular atypia, mitotic figures, and neo-vasculature at 
the tumor site. 
 In spite of the close similarities between our high grade glioma models 
and their corresponding parent tumors, a few features are lacking. One such 
feature that is not present in our models is necrosis (hypoxic areas surrounded 
by hypercellular zones called pseudopalisades) that would be expected in 
xenografts derived from GBM (Rong et al 2006). One possible explanation for the 
lack of necrosis in our model may be related to our cell selection procedure that 
may exclude cells responsible for the development of necrotic areas (Brat et al 
2004).  
  The atypical characteristics observed in our low grade glioma models are 
interesting and suggest several possible reasons behind this phenomenon. The 
uncharacteristic malignant features (Fig 3.9) and metastatic growth in lymph 
nodes (Fig 3.8) were observed in the five low grade tumors that had successful 
engraftment of xenotransplanted cells. One important factor in our model that 
may contribute to the development of such atypical features is the use of a 
severly immunocompromised (NOD/SCID) host (Shultz et al 1995) that lacks 
both innate and adaptive immune response. Non-obese diabetic with severe 
combined immunodeficiency disease (NOD/SCID) mice lack function B and T 
cells and extremely attenuated NK cell response (McCormack et al 2005). Usage 
of this particular strain of mice enabled us to transplant human primary tumor 
cells successfully in an animal without concern for immunological rejection. 
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However, it is possible that low grade tumors’ interaction with this particular host 
environment may underlie, at least in part, the aggressive and metastatic 
phenotype seen in the mice.  
However, the aforementioned reasoning alone does not suffice to explain 
the atypical features since we didn’t observe these characteristics in our high 
grade glioma models. An alternate possibility is that the low grade tumors may 
possess the ability or the specific cell type to develop into aggressive tumors in 
patients, but this phenotype is kept under control by the patient’s immune 
surveillance system. Being transplanted into an immunocompromised host, the 
malignant phenotype of low grade glioma emerges. Further experiments which 
involve primary tumor xenotransplantation into different mouse strains that vary 
in the degree of immune response may provide additional insight into the 
biological basis for this phenomenon. 
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CHAPTER IV  
 
ROLE OF THE HEDGEHOG PATHWAY IN MALIGNANT GLIOMA GROWTH 
 
Abstract 
Hedgehog pathway activity has been demonstrated in malignant glioma. 
However, its role in tumor growth has not been determined. Here we 
demonstrate that pharmacological inhibition of the Hedgehog pathway in 
established orthotopic malignant glioma xenografts confers a survival advantage. 
Pathway inhibition is measured in transplanted human tumor cells and not in host 
mouse brain. Correspondingly, survival benefit is observed only in tumors with an 
operational Hedgehog pathway. These data indicate that Hedgehog signaling 
regulates the growth of select malignant gliomas. We also demonstrate that 
Hedgehog pathway component and gene target expression segregate to 
CD133+ tumor initiating cells. Treated mice eventually succumb to disease, thus 
targeting the Hedgehog pathway in CD133+ cells produces significant, but 
incomplete tumor regression. Therefore, our studies suggest that more complete 
tumorregression may require the inclusion of other therapeutic targets, including 
CD133- cells. 
 
Introduction 
Malignant gliomas are characterized by invasive growth that is intractable to 
current therapies. One glioma cell type that confers resistance to radiation and 
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chemotherapy has been identified by the expression of CD133 (Prominin-1) (Bao 
et al 2006a, Liu et al 2006). Multipotent CD133+ cells have the capacity to initiate 
and passage disease in immunodeficient mice (Bao et al 2006b, Piccirillo et al 
2006, Singh et al 2004b), and thus represent at least one cellular component that 
can maintain aggressive glioma growth. Commonly referred to as tumor-initiating 
or cancer stem cells, the identification of CD133+ cells in malignant glioma has 
prompted the characterization of regulatory molecular pathways for therapeutic 
strategies. 
Among signaling mechanisms that regulate stem cell self-renewal and 
commitment (Ahn and Joyner 2005, Trowbridge et al 2006), Hedgehog (Hh) 
pathway activation has been demonstrated in a subset of malignant gliomas (Bar 
et al 2007, Clement et al 2007, Ehtesham et al 2007, Xu et al 2008). However, 
the role of Hh signaling in glioma growth has not been determined as prior 
studies involved manipulations to inhibit the Hh pathway in cultured cell lines for 
in vitro assays and prior to xenotransplantation. Glioma cells are known to 
undergo phenotypic and genotypic transformation in culture (Lee et al 2006). 
Therefore, we have initiated pathway inhibition in established glioma orthotopic 
xenografts from freshly resected patient specimens to test rigorously the 
requirement for Hedgehog signaling in tumor growth. Hh signal transduction 
components and small molecule modulators have been well characterized 
(Rohatgi and Scott 2007, Rubin and de Sauvage 2006). Smoothened, a seven-
pass transmembrane domain protein that is strictly required for signal 
transduction (Zhang et al 2001), has been a common target of nonbiased small 
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molecule screens (Chen et al 2002b, Frank-Kamenetsky et al 2002). For our 
experiments, pharmacological inhibition was mediated by cyclopamine, a 
Smoothened inhibitor (Chen et al 2002a) that has been well-tolerated and 
effective for in vivo (Berman et al 2002, Karhadkar et al 2004). 
 
Materials and Methods 
 
Tissue procurement 
Excess brain tumor specimens were obtained for research purposes from 
patients in accordance with a protocol approved by Vanderbilt Medical Center 
Institutional Review Board. Primary brain tumors were phenotyped and graded 
as described (Kleihues et al 1995, Kleihues et al 2002). 
Immunohistochemical analysis of tumors 
Immunodetection was performed for Ki67 (1:50; Dako) on paraffin-embedded 
sections and for anti-human nuclear epitope (1:50; Chemicon) on frozen sections 
as described (Ehtesham et al 2007). 
 
CD133 immunomagnetic cell selection 
Tumor samples were minced mechanically, dissociated with papain (Worthington 
Biochemical Corporation), and passed through a 40 µm filter. Cells were labeled 
with a CD133/1 (15 µg/ml; Miltenyi Biotec) antibody crosslinked to magnetic 
nanoparticles and subjected to immunomagnetic cell separation using the 
EasySep Magnetic Selection Kit (Stem Cell Technologies). Purity of the CD133-
enriched population was assessed by flow cytometry after labeling enriched  cells 
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with CD133/2-APC (Miltenyi Biotec) antibody. CD133-enriched and CD133-
depleted populations were then incubated with PTCH antibody (1:200; Santa 
Cruz Biotechnologies, G19 Lot # J2505), followed by AlexaFluor-488 secondary 
antibody labeling (1:1000; Invitrogen) and analyzed by flow cytometry. Isotype-
matched controls were included in the analysis to determine background signal 
levels. Gates thresholds were set relative to the CD133 negative-selection 
samples. A portion of the CD133- enriched and CD133-depleted fractions were 
also used for gene expression measurements using quantitative qRT-PCR. 
 
Orthotopic xenotransplantation 
104-105 CD133-enriched cells were transplanted into the striatum of NOD/SCID 
mice according to a protocol approved by the Vanderbilt Medical Center 
Institutional Animal Care and Use Committee. Mice were anesthetized with 
ketamine and xylazine, and securely placed on a stereotactic frame. Using 
aseptic surgical procedures, an incision was made in the scalp and a small burr-
hole was drilled 2.5 mm lateral to the bregma. CD133-enriched cells were 
implanted 2.5 mm into the right striatum using a Hamilton syringe. Mice were 
maintained until development of neurological symptoms or signs of distress 
(piloerection and/or hunched posture).  
 
Gliomasphere cell culture and Hh signaling assays 
Tumor samples were dissociated (Papain, Worthington Biochemical 
Corporation). Cells were plated in non-treated polystyrene flasks (BD-Falcon) in 
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NeuroCult medium with supplements (NeuroCult® NS-A Proliferation Kit; Stem 
Cell Technologies), 2 g/mL heparin (Sigma), 20 ng/mL EGF (ProSpec 
TechnoGene), 10 ng/mL bFGF (ProSpec TechnoGene), and 1X Penicillin-
Streptomycin (Invitrogen). GS were transferred to multiwell plates and cultured in 
triplicate for 40 hours either alone, with 50 nM SAG, or 200nM SANT1. GLI1 and 
GAPDH levels were measured by qRT-PCR as described below. 
 
RNA extraction, cDNA synthesis, and qRT-PCR 
Total RNA was extracted from brain tissue and GS cells with the PureLink™ 
RNA Mini Kit (Invitrogen). Genomic DNA was removed (RNase-Free DNase Set; 
QIAGEN) and purified RNA quantified (RiboGreen RNA Quantitation Kit; 
Invitrogen). Single-stranded cDNA was synthesized with oligo(dT) and random 
hexamer primers (iScript cDNA Synthesis Kit; Bio-Rad). For negative controls, 
reverse transcriptase was omitted from the synthesis reaction (-RT). qRT-PCR 
was performed in triplicate for each sample and on the corresponding –RT 
control with TaqMan® Fast Universal PCR Master Mix (Applied Biosystems; 
ABI), cDNA template, and ABI’s TaqMan® Gene Expression Assay for hPTCH 
(Hs00970979_m1), hGLI1 (Hs00171790_m1), hGAPDH (Hs99999905_m1), 
hCD133 (Hs01009261_m1), hSHH (Hs00179843_m1), mGli1 
(Mm00494654_m1), or mGAPDH (Mm99999915_g1). For standard curves, qRT-
PCR was performed on serial dilutions of a cDNA mixture (Ehtesham et al 2007). 
For each amplicon, quantities were determined according to the standard curve 
method (User Bulletin #2, PE Applied Biosystems).  
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Results 
Cyclopamine confers a survival benefit in established glioma xenografts 
Malignant gliomas were modeled in NOD/SCID mice by orthotopic 
transplantation of CD133+ cells enriched from four primary tumor (PT) 
specimens on the day of resection (Table 1). Reflecting the heterogeneous 
phenotypes encompassed by WHO grades III  and IV malignant glioma, the 
patient tumors included an anaplastic oligoastrocytoma (PT-304-AOA), a high-
grade astrocytoma (PT-312-HGA), an anaplastic ganglioglioma a rare malignant 
glioma phenotype; PT-302-AG) and a primary GBM (PT-406-GBM).  From these 
specimens, xenotransplanted tumors formed with variable, but generally high, 
rates of engraftment (69-100%) and the median length of survival ranged from 
64.5-145 days.  
Engraftment of transplanted cells could be visualized by hematoxylin and 
eosin (H&E) staining, in conjunction with immunohistochemistry for markers of 
cell proliferation (Ki67; Figure 4.1a, 4.1c and 4.1e; X-304-AOA, X-312-HGA, and 
X-406-GBM) or a panhuman nuclear epitope (anti-human nuclear; data not 
shown; X-302-AG) (Uchida et al 2000). Recapitulation of malignant glioma 
pathological features was observed and included infiltrative growth, invasion of 
the corpus callosum to the 5 contralateral hemisphere, and pleomorphic nuclei 
with mitotic figures (Figure 4.1a, 4.1c, and 4.1e). As the Hh pathway is activated 
in subsets of malignant glioma specimens (Bar et al 2007, Clement et al 2007, 
Ehtesham et al 2007, Xu et al 2008), we first sought to determine the operational 
status of the Hh pathway in these malignant glioma specimens. 
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Gliomaspheres (GS) were generated successfully from an unsorted portion for 
three of the four specimens (GS-304-AOA, GS-312-HGA, and GS-406-GBM) 
under culture conditions that are required for eliciting a Hh pathway response in 
glioma primary cell cultures (Ehtesham et al 2007). Addition of a Smoothened 
agonist (SAG, 50 nM) (Frank-Kamenetsky et al 2002) to GS-304-AOA and GS-
312-HGA induced a 4-fold increase in hGLI1 mRNA expression (p < 0.05, 
Student’s T-test; Figure 4.1b and 4.1d) suggesting an operational Hh pathway in 
these primary tumors. In contrast, GS-406- GBM cells did not respond to SAG 
treatment (Figure 4.1f) suggesting that this tumor lacks an operational Hh 
pathway. Consistent with previous Hh signaling assays in GS (Ehtesham et al 
2007), basal levels of pathway activity were not reduced by treatment with a 
Smoothened antagonist (SANT1, 200 nM; Figure 4.1b, 4.1d and 4.1f) (Chen et al 
2002b). 
To determine the effect of in vivo Hh pathway inhibition on established 
tumors for which the operational status of the Hh pathway had been assayed in 
GS culture, X-304-AOA, X-312-HGA and X-406-GBM mice were treated with 
cyclopamine and assayed for survival. The survival studies were performed at 
initial transplantation (X-304-AOA and X-312-HGA) or first passage (X-406-
GBM), depending upon adequate patient or xenograft material to generate 
sufficient numbers of mice. The mice were 6 randomized to receive either 
cyclopamine or vehicle after the first animal of a cohort became symptomatic and  
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Table 4.1. Clinical and pathological features of malignant gliomas 
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Figure 4.1. Characterization of tumor pathology in xenografts and Hedgehog (Hh) pathway responsiveness in 
gliomaspheres generated from malignant gliomas. Malignant glioma specimens were dissociated with papain 
and divided into two portions. On the day of resection, one portion was enriched for CD133þ cells by 
immunomagnetic selection and transplanted directly into the striatum of NOD/SCID mice. The other portion 
was plated in NeuroCult media with bFGF and EGF for gliomasphere (GS) culture. (a, c and e) Tumor 
engraftment was revealed by hematoxylin and eosin (H&E) and Ki67 staining from an anaplastic 
oligoastrocytoma (X-304- AOA), a high-grade astrocytoma (X-312-HGA) and a GBM (X-406-GBM). 
Xenotransplanted tumors recapitulated distinct features of high-grade glioma, namely infiltrative growth with 
invasion of the corpus callosum (black arrowheads) to involve the contralateral hemisphere (insets) and the 
leptomeninges (yellow arrowhead). Under high-power magnification, similar cell density and morphology was 
observed for each xenograft and the corresponding patient tumor (scale bar¼50 mm; red arrowheads indicate 
mitotic figures). (b, d and e) Hh pathway response was assayed in GS cultured for 40 h in the presence of 
either vehicle (VEH), a Smoothened agonist (SAG; 50 nM) or a Smoothened antagonist (SANT1; 200 nM). In 
triplicate cultures for each cell line and culture condition, hGLI1 levels were normalized to hGAPDH and 
expressed relative to vehicle-treated control GS. Relative hGLI1 mRNA levels were significantly elevated 
by SAG treatment in GS-304-AOA and in GS-312-HGA. In contrast, no response was elicited in GS-406-GBM. 
*Pp0.05. 
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was determined to have engraftment (Figure 4.1). Following published protocols, 
mice were treated by intraperitoneal injection with 25 mg/Kg/day of cyclopamine 
(Sanchez et al 2004, Sanchez and Ruiz i Altaba 2005). By this method, a 
significant survival benefit was observed only for X-304-AOA (p = 0.029, Logrank 
test; Figure 4.2a and data not shown). For the X-304-AOA survival study, 
treatment with either cyclopamine (25 mg/Kg/day; n=6) or vehicle (10% 2-
Hydroxypropyl-ß-cyclodextrin; n=6) was initiated 90 days following 
transplantation, and was administered for 30 days. In the vehicle treatment 
group, 4 mice developed tumor and the median survival time as 124 days. In the 
cyclopamine treatment group 4 mice developed tumor and the median survival 
time was 190.5 days. The remaining mice (2 vehicle- and 2 cyclopamine- 
treated) were sacrificed 270 days after xenotransplantation and determined not 
to have engraftment. Thus, cyclopamine treatment conferred a median survival 
difference of 66.5 days (Figure 4.2a). 
The lack of survival benefit in the X-312-HGA and X-406-GBM mice 
suggests that within these xenografts either an insufficient level or duration of 
pathway inhibition was achieved with daily dosing, or that the Hh pathway is not 
operational in these tumors. To test the first possibility, we determined the 
optimal dose and delivery schedule for cyclopamine. Because of limitations 
inherent to a direct orthotopic xenotransplantation model, namely the availability 
of sufficient CD133+ cells for passaging tumor in large numbers of animals and 
relatively slow growth kinetics, X-302-AG mice were used for dosage titration  
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Figure 4.2. Hedgehog (Hh) pathway inhibition confers a survival advantage. (a) 90 days 
after xenotransplantation, X-304-AOA mice were treated for 30 days with either cyclopamine 
(25 mg/kg/day) or vehicle. The median survival for cyclopamine-treated mice was 66.5 days 
longer than for vehicle-treated controls (P¼0.029, Logrank test). (b) Treatment was initiated 
in X-312-HGA mice 50 days after xenotransplantation and continued for the duration of the 
survival study. Cyclopamine-treated mice (50 mg/kg twice daily) had a median survival of 
11.5 days longer than vehicle-treated mice (P¼0.0062, Logrank test). (c) Continuous 
cyclopamine treatment of X-406-GBM mice (50 mg/kg twice daily starting 100 days after 
xenotransplantation) did not enhance survival (P¼0.56, Logrank test). Solid gray bars 
indicate duration of treatment. BID, twice daily. 
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studies while X-312-HGA and X-406-GBM were undergoing serial passage. X-
302-AG mice were injected with varying doses of 7 cyclopamine (25-100 mg/Kg)  
and then sacrificed at varying times after injection (1.5-16 hours). Using species-
specific primers, the expression levels of human GLI1 (hGLI1) and human 
GAPDH (hGAPDH) were measured in a portion of the injected hemisphere by 
quantitative real-time PCR (qRT-PCR). We measured suppression of hGLI1 
expression in X-302-AG mice treated with cyclopamine, with maximal repression 
at 50 mg/Kg. Furthermore, hGLI1 inhibition was transient, with maximal inhibition 
measured at 5 hours after injection and hGLI1 expression levels returning to 
baseline by 16 hours (data not shown). We therefore determined that injecting 
cyclopamine at 50 mg/Kg twice a day provides more complete and durable 
pathway inhibition than 25 mg/Kg/day. Thus to determine the operational status 
of the Hh pathway in X-312-HGA and X-406-GBM, mice were treated with either 
cyclopamine (50 mg/Kg/twice daily) or vehicle (twice daily). After one week of 
treatment, relative hGLI1 expression was determined by qRTPCR in vehicle (n=3 
for each tumor) and cyclopamine (n=3 for each tumor) treated animals. Inhibition 
of hGLI1 was observed for X-312-HGA (85%, p = 0.036, Student’s T-test) 
indicating an operational Hh pathway that can be modulated in vivo (Figure 4.3a). 
In contrast, relative hGLI1 levels were not inhibited by cyclopamine treatment in 
X-406-GBM (Figure 4.3a). The inability to modulate hGLI1 by small molecules in 
either in vitro (GS-406-GBM) or in vivo (X-406-GBM) assays (Figures 4.1f and 
4.3a, respectively) suggests that the Hh pathway is not operational in this GBM. 
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Hh pathway activity in malignant glioma is ligand-dependant (Bar et al 
2007, Clement et al 2007, Ehtesham et al 2007). Therefore, we assayed for 
human Shh (hSHH) mRNA expression in transplanted cells. Notably, hSHH 
expression can be measured in X-312-HGA, X-304-AOA and X-302-AG, but not 
in X-406-GBM (Figure 4.3b). 
Collectively, the in vitro (GS-312-HGA, GS-304-AOA and GS-406-GBM), 
in vivo (X-312-HGA, X-304-AOA, X-302-AG and X-406-GBM) and hSHH 
expression (X-312-HGA, X-304-AOA, X-302-AG and X-406-GBM) studies 
identify Hh-responsive and non-responsive tumors. Furthermore, pathway activity 
may be directly related to active ligand production within the Hh-responsive 
tumors. Thus, given the evidence supporting an operational Hh pathway in X-
312-HGA, we performed another survival study using more potent and durable 
cyclopamine dosing. By this method, continuous treatment with cyclopamine (50 
mg/Kg twice daily) conferred a median survival difference of 11.5 days (p = 
0.0062; Logrank test) in X-312-HGA mice (Figure 4.2b). Conversely, no 
difference in survival was measured in X-406-GBM mice receiving continuous 
treatment with a maximally inhibitory dose of cyclopamine (50 mg/Kg twice daily; 
Figure 4.2c). 
The survival advantage from in vivo Hh inhibition in malignant gliomas with 
an operational pathway (X-304-AOA and X-312-HGA) indicates that Hh signaling 
regulates glioma growth. Notably, the degree of enhanced survival varies among 
Hh-responsive xenografts and the dosage of cyclopamine. This may relate to 
differences in growth kinetics of the two Hh-responsive xenografts. Survival was  
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Figure 4.3. Cyclopamine treatment inhibits the Hedgehog (Hh) pathway within 
xenotransplanted glioma cells. (a) Mice bearing malignant glioma xenografts were treated 
for 1 week with either vehicle (twice daily; n¼3 for each tumor type) or cyclopamine 
(50mg/kg twice daily; n¼3 for each tumor type). Using species-specific primers, human 
GLI1 levels were normalized to hGAPDH and mouse GLi1 (mGLI1) levels were normalized 
to mGAPDH. Relative hGLI1 mRNA levels were significantly decreased in X-312-HGA 
cyclopamine-treated mice. No significant inhibition of hGLI1 was observed in X-406-GBM 
cyclopamine-treated mice. Relative mGLI1 mRNA levels were not altered by cyclopamine 
treatment in any of the malignant glioma xenografts. (b) Human Shh (hSHH) mRNA 
expression was detected in 6/6 X-312-HGA, 3/3 X-304-AOA, 6/6 X-302-AG and 0/6 X-406-
GBM xenografts (normalized to hGAPDH and expressed as average ± s.e.m.). ND, not 
detected; *Pp0.05. 
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monitored in both treatment groups until death or endpoint criteria, and all of the 
mice in the cyclopamine treatment groups eventually died of disease(Figure 4.2). 
 
Cyclopamine mediates Hedgehog pathway inhibition in transplanted human 
glioma cells and not in host neural parenchyma  
Recent studies pertaining to epithelial-derived malignancies demonstrate that 
tumor-derived Shh ligand supports  growth by generation of host stromal tissue 
(Yauch et al 2008). Using species-specific primers, we find that cyclopamine 
treatment modulates hGLI1 and not mGli1 expression (Figure 4.3a). These 
results suggest that survival benefits observed in cyclopamine- treated X-304-
AOA and X-312-HGA mice are not related to Hh pathway inhibition within host 
neural parenchyma, but rather in transplanted glioma cells. 
 
PTCH and GLI1 expression segregate to CD133+ cells in malignant glioma 
xenografts  
Within malignant gliomas, expression of the Hh receptor Patched (PTCH) has 
been detected in cells with stem or progenitor cell features (Ehtesham et al 
2007). To gain a better understanding of the glioma cellular compartments in 
which the Hh pathway might be operational, we evaluated PTCH expression by 
flow cytometry in the CD133positive- and CD133negative-selection cell 
populations from freshly resected tumors following immunomagnetic sorting. 
PTCH+ cells were highly enriched in the CD133positive-selection fraction and 
depleted from the CD133 negative-selection fraction from PT-312-HGA,  
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Figure 4.4. PTCH expression segregates with CD133þ cell selection within malignant glioma. (a) Expression of the 
Hedgehog (Hh) receptor PTCH was analysed by flow cytometry in CD133-positive and CD133-negative selection 
cell populations. Analysis of PT-312- HGA revealed enrichment of PTCHþ cells with CD133-positive selection, and 
their absence in the CD133-negative selection cell populations. Similar results were obtained with analysis of 
xenotransplanted tissue from X-304-AOA. In contrast, PTCH expression did not segregate with CD133-positive or -
negative selection of the Hh-nonresponsive PT-406-GBM specimen. (b) Unsorted, CD133- enriched and CD133-
depleted cells from X-302-AG were analysed by quantitative real-time PCR (qRT–PCR) for expression of hCD133, 
hGLI1, hPTCH and hGAPDH. The expression levels of hCD133, hGLI1 and hPTCH, relative to hGAPDH, were 
significantly elevated by CD133 positive selection. ND, not detected. 
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suggesting confinement of pathway responsiveness to CD133+cells (Figure 
4.4a). Likewise, PTCH expression segregated with CD133+ cell selection of X-
304-AOA (Figure 4.4a). In contrast, there was no significant detection or 
segregation of PTCH expression in CD133-selected cell populations from PT-
406-GBM (Figure 4.4a), consistent with the lack of in vitro or in vivo response to 
pathway  modulation in this tumor. 
To corroborate and expand these findings, mRNA expression levels of the 
Hh pathway components and gene targets hPTCH and hGLI1 were measured in 
CD133 positive- and CD133 negative-selection cell populations following 
immunomagnetic sorting of X-302-AG. Compared to unsorted cells, elevated 
hGLI1 and hPTCH mRNA levels were detected in the CD133-enriched samples, 
and either not detected (hGLI1) or reduced (hPTCH) in the CD133-depleted 
samples (Figure 4.4b). Taken together, these data suggest pathway inhibition is 
mediated in CD133+ cells and that CD133- cells are not directly affected by 
cyclopamine treatment.  
 
Discussion 
These studies demonstrate that Hh pathway inhibition in established malignant 
glioma xenografts confers a significant survival advantage. Notably, survival 
studies performed in three xenotransplanted tumors reveal that the benefit of 
cyclopamine treatment is not uniform within the spectrum of malignant glioma. 
One key difference is the presence of an operational Hh pathway. Hh pathway 
activation can only be demonstrated in a subset of malignant gliomas in broad 
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surveys of patient samples (Bar et al 2007, Clement et al 2007, Ehtesham et al 
2007, Xu et al 2008). This trend was observed in our studies of more limited 
sample size, by the identification of Hh responsive and non-responsive 
xenografts. Furthermore, and of importance for preclinical studies, the ability to 
modulate the Hh pathway in vitro has predictive value for in vivo modulation, as 
demonstrated by studies with GS-312-HGA and X-312-HGA. In support of this 
concept, hGLI1 levels could not be induced or suppressed in GS-406-GBM or X-
406-GBM, respectively. 
Another example of nonuniformity in cyclopamine response was observed 
between the two Hh-responsive xenografts. A longer survival benefit was 
measured for X-304-AOA mice with a lower dose and duration of cyclopamine 
treatment than for X-312-HGA. Many factors may have influenced this difference 
including prior treatment in the patient, tumor engraftment rate and growth 
kinetics, or cell selection pressures of tumor passage. With regard to tumor 
growth kinetics, in this study cyclopamine treatment was initiated after the first 
animal of a cohort developed symptoms. Thus for the more slow-growing X-304-
AOA, treatment was initiated earlier in the course of disease (day 90 with a 
median survival of 124 days in control animals). In contrast, X-312-HGA 
displayed faster growth kinetics as all mice bearing the initial xenotransplant died 
or met criteria for sacrifice within a span of 7 days following initiation of treatment 
with cyclopamine at 25 mg/Kg/day. These observations suggest a greater 
survival benefit may be obtained with initiation of pathway inhibition earlier in the 
course of tumor growth. Future studies to address these differences in 
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cyclopamine response would benefit from the use of small-animal imaging to 
establish tumor engraftment and thus enable earlier treatment initiation. 
Prior studies pertaining to Hh signaling and ligand-independent growth of 
medulloblastoma have utilized systemic doses of cyclopamine as low as 10 
mg/Kg very other day to achieve meaningful pathway inhibition in the cerebellum 
(Sanchez and Ruiz i Altaba 2005). Our results indicate that much higher doses of 
cyclopamine are required for inhibiting the growth of gliomas with ligand-
dependent Hh pathway activation. This difference in sensitivity is consistent with 
the hypothesis of “oncogene-addiction” (Weinstein and Joe 2008), such that 
lower doses of cyclopamine are sufficient for medulloblastoma in which tumor 
initiation and growth are associated with constitutive activation of the Hh pathway 
by loss of PTCH function (Berman et al 2002). 
With regard to Hh-dependant tumor growth, signaling within either tumor 
cells or host tissue has been demonstrated, depending upon the tumor type 
(Berman et al 2002, Yauch et al 2008). Our studies indicate that in the case of 
malignant glioma, cyclopamine inhibits the Hh pathway in xenotransplanted cells 
and not in host cerebrum. 
In this context, our observation that a survival advantage can be 
demonstrated only in mice xenotransplanted with Hh-responsive gliomas argues 
strongly that this benefit is a result of cyclopamine-mediated Hh pathway 
inhibition and not due to off-target effects. We have previously demonstrated a 
requirement for the addition of exogenous Hh ligand to induce a pathway 
response in primary GS cultures (Ehtesham et al 2007). Furthermore, the Hh 
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pathway in GS appears to be at a basal level as the addition of SANT1 does not 
reduce relative hGLI1 levels. Thus the finding from our in vivo model that 
transplanted cells generate hSHH transcript, indicates that Shh production is not 
maintained under these GS culture conditions. Notably, hSHH transcript is 
detected only in Hh-responsive xenografts and suggests that tumor cells may be 
a source of ligand. Whether this underlies autocrine or paracrine signaling among 
glioma cells has not been addressed in these studies. 
Within solid and hematologic cancers, the frequency and phenotypes of 
tumorigenic cells in transplantation models remain to be fully characterized (Kelly 
et al 2007, Quintana et al 2008). However, to date CD133 is the best 
characterized surface marker for prospective isolation of tumor-initiating cells 
from malignant glioma. Despite several caveats, the concept of tumor-initiating 
cells provides a framework for conceptualizing the cellular heterogeneity of 
tumors, with a hierarchical arrangement of multipotent tumor cells giving rise to 
transient amplifying progenitor and ultimately postmitotic cells (Barker et al 2009, 
Clarke et al 2006, Zhu et al 2009). The segregation of Hh pathway components 
and gene targets, PTCH and GLI1, to CD133+ cells suggests that CD133- cell 
behavior is not subject to Hh pathway regulation. Thus, CD133- transient 
amplifying cells (Ligon et al 2007) might contribute to tumor growth in spite of 
cyclopamine treatment. Additionally, the CD133- compartment may contain other 
Hh-unresponsive tumor-initiating cells, as CD133- cells isolated directly from 
malignant gliomas have been shown to engraft in nude rats (Ogden et al 2008). 
Therefore, greater tumor regression might be achieved by combining Hh pathway 
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inhibition with therapies directed at other glioma cell types such as CD133- 
transient amplifying cells or other tumor-propagating cells. 
Common approaches for modeling human cancer in mice include germ-
line genetic modification or xenotranplantation (Fomchenko and Holland 2006, 
Gutmann et al 2006, Shu et al 2008, Suggitt and Bibby 2005). In these studies, a 
direct orthotopic glioma xenotransplantation model was utilized to reduce the 
potential for cell transformation in culture (Lee et al 2006). Inherent limitations of 
this model include availability of adequate patient material and initial engraftment 
rate, the number of CD133+ cells available for initial transplantation and 
subsequent passage and relatively slow growth kinetics. Importantly though, it 
has afforded the opportunity to: (i) define the presence or absence of an 
operational Hh pathway in an array of malignant glioma specimens; (ii) determine 
the optimal inhibitory dose and delivery schedule for cyclopamine; (iii) identify the 
glioma cell type in which Hh signaling occurs; and (iv) demonstrate enhanced 
survival by pharmacological inhibition of Hh signaling. These findings indicate 
that Hh signaling regulates the growth of select malignant gliomas, and the utility 
of targeting this pathway in a preclinical model. 
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CHAPTER V  
 
CONCLUSIONS 
 
Understanding mechanisms that regulate glioma growth is crucial to the 
development of targeted therapies. Our studies demonstrate that Hh signaling 
within gliomas represents an important mechanism that supports tumor growth. 
An important aspect of our work demonstrates that the Hh pathway is activated 
and operational only in distinct glioma subtypes (summarized in Figure 5.1).  This 
distinction will be of fundamental value in designing clinical trials to investigate 
the use of Hh pathway inhibitiors in primary brain tumors. Furthermore, we have 
found that the pathway is operational in stem-like cells within specific glioma 
subtypes. An essential accomplishment in our studies pertaining to the biological 
role of Hh signaling in glioma growth was the development of a relevant 
preclinical model. In the process of creating direct orthotopic xenotransplantation 
models, we made an interesting observation. Malignant glioma primary 
xenografts faithfully recapitulated hallmark features of patient pathology. In 
contrast, low grade glioma primary xenografts demonstrated atypical features 
after xenotransplantation that raised interesting questions regarding the tumor-
host interaction within these gliomas and illustrated a limitation of our model – 
namely, the use of severely immunocompromised mice that does not fully 
represent the immune response of host to the tumor tissue. 
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Figure 5.1. Survey of Hh pathway in malignant gliomas. PTCH mRNA expression levels in 
malignant glioma specimens were expressed as the fold-difference relative to control human 
brain tissues. On the left half of the graph are the numbers of specimens with ≥ 3-fold (red) 
and < 3-fold (blue) differences. To assay Hh pathway activity in primary gliomaspheres 
(GS), PTCH and GLI1 mRNA levels were measured following culture in the presence or 
absence of purified Shh protein or pathway-specific small molecule modulators. On the right 
half of the graph are the numbers of primary cell lines in which a significant pathway 
response was present (red) or absent (blue). These findings demonstrate that many WHO 
grade II and III gliomas contain an operational Hh pathway. 
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 Figure 5.2. Characterization of the Hedgehog pathway in malignant gliomas. (a-j) On the 
day of resection, a high-grade astrocytoma (312-HGA) and a glioblastoma (406-GBM) 
specimen were dissociated with papain. One portion was transplanted directly into 
NOD/SCID mice and the other portion was plated in gliomasphere culture conditions. Similar 
histological features were observed for each xenograft (a and f) and the corresponding 
patient tumor (b and g; scale bar = 50 µm; red arrowheads indicate mitotic figures). An in 
vitro Hedgehog pathway response (GLI1 induction) was measured in gliomaspheres 
cultured in the presence of either vehicle (VEH), a Smoothened agonist (SAG, 50 nM) or a 
Smoothened antagonist (SANT1, 200 nM) for 312-HGA (c), but not for 406-GBM (h). An in 
vivo Hedgehog response (human GLI1 inhibition) was measured in mice bearing malignant 
glioma xenografts treated for one week with either vehicle or cyclopamine (a Smoothened 
antagonist; 50 mg/Kg twice daily), for 312-HGA mice (d). No significant inhibition of human 
GLI1 was observed in X-406-GBM mice (i). Hedgehog pathway inhibition (cyclopamine 50 
mg/Kg twice daily for 30 days) confers a survival advantage for 312-HGA mice (e; p = 
0.0062, Logrank test). Continuous cyclopamine treatment of X-406-GBM mice does not 
enhance survival (j; p = 0.56, Logrank test). 
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Figure 5.3. Schematic diagram of the role of Hh signaling in gliomas. The diagram illustrates 
that Shh signaling regulates glioma growth by acting on CD133+ cells. Its specific role in 
regulation CD133+ cell self-renewal or commitment mechanisms needs further 
investigation. 
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Figure 5.4. Schematic diagram of the cell type that Hh signaling regulates. The diagram 
illustrates that Shh signaling regulates glioma growth by acting on CD133+ cells. These 
cells may be part of a larger group of tumor-initiating cancer stem cells that initiates and 
maintains growth of tumor cells within gliomas. 
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One important question to consider in our studies is the reason behind the 
differential status of Hedgehog signaling in glioma subtypes. Our results indicate 
that the pathway does not play an operational role in de novo GBMs. This was 
confirmed by gene and protein expression analysis (Figure 5.1), in vitro signaling 
assays and, to a limited extent, in vivo preclinical studies (summarized in Figure 
5.2). However, one potential alternative explanation for the disparity could be 
sampling variability in tissue selection. Since GBMs are known to be extremely 
heterogeneous in tissue histology, it is possible that the portions of tissue 
selected for individual experiments, analysis and xenotransplantation varied in 
their Hh pathway activation profile. However, this possibility seems unlikely owing 
to the consistent trend that was observed across several GBM samples. 
Additional preclinical studies using several GBM xenograft models can further 
support our hypothesis that the Hh pathway does not play an operational role in 
GBMs. 
Our results suggest that regulation of CD133+ cells, and subsequently 
tumor growth, within GBMs could be driven by molecular mechanisms 
independent of the Hh pathway. For example, the EGF signaling pathway 
components are known to be over-expressed in GBMs suggesting the prominent 
role of tyrosine-receptor-kinase (TRK) signaling in GBM growth. It is possible that 
GBM growth relies on one or more TRK signaling mechanisms and circumvents 
the involvement of the Hh pathway. If so, then treatment with the Hh pathway 
inhibitors may have no direct effect in GBMs as suggested by our preclinical 
studies. However, two interesting avenues of research emerge from our data. Hh 
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signaling may play an early role in regulating CD133+ cells that is suppressed, or 
inactivated, later in the development of GBMs. This could explain the results from 
our data, which relies on analysis from fully established GBM patient samples. To 
test this question, we can use transgenic animal models that faithfully 
recapitulate the development stages of GBM, thus allowing us to study the 
kinetics of pathway activation if the Hh pathway does play a role at specific 
periods of GBM development. Another interesting question to explore will be the 
role of the pathway in the development of secondary GBM, which are a clinically 
and molecularly distinct entity, compared to primary GBM. As alluded to in 
Chapter 2, access to larger number of secondary GBM patient samples will allow 
us to more carefully evaluate the role of the Hh pathway in this particular glioma 
subtype. 
Another interesting question that merits investigation relates to the specific 
biological role that the Hh pathway plays in regulating CD133+ cells. As 
illustrated in Figure 5.3, it remains to be seen whether the pathway specifically 
regulates the self-renewal mechanism of CD133+ cells or the commitment phase 
to transit-amplifying progenitor cells. Based on studies related to the pathway’s 
role in adult neural stem cell maintenance (Ahn and Joyner 2005) one would 
expect the pathway to control self-renewal of CD133+ cells. However, an 
intriguing possibility could emerge if Hh pathway is found to regulate CD133+ cell 
commitment. If so, this may suggest that blocking the pathway could lead to a 
relative increase in the number of CD133+ cells as they continue to self-renew 
without transitioning towards lineage commitment. If this blockade of commitment 
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underlies the reason behind the survival advantage in our glioma models, then 
we can infer that continuous inhibition of the Hh pathway would be necessary to 
prevent regrowth of tumor from the accumulated CD133+ cells upon release from 
pathway inhibition. Moreover, this suggests that blocking CD133+ cell 
commitment may slowly deplete tumors from a continuous source of rapidly-
dividing progenitor cells. 
Additionally, our results suggest that enhanced anti-tumor benefit can be 
achieved by a method of combination therapy using Hh pathway inhibitors that 
could take many forms. For example, targeting both CD133+ and CD133- cells 
could ensure that all cellular components of a tumor are eliminated. Owing to the 
elevated multi-drug resistance mechanisms of cancer stem cells, it is possible 
that enhanced benefit can be achieved by pairing Hh pathway inhibitors with 
multi-drug transport inhibitors that can increase retention of drugs within cancer 
stem cells. Alternately, combining Hh pathway inhibitors with known 
chemotherapeutic drug regimens could eliminate the highly proliferative 
component of the tumor along with effects on CD133+ cells. Further elucidation 
of parallel molecular signaling pathways that can regulate both CD133+ and 
CD133- cells will allow us to explore combination therapies that exploit the 
dependency of tumor cells on Hh and other pathways. 
Another intriguing model, illustrated in Figure 5.4, may also predict 
treatment success based on Hh pathway inhibition. The model suggests that 
CD133+ cells may form one compartment of a larger group of tumor-initiating 
cancer stem cell population. Cancer stem cells, as defined by their shared 
  101 
properties of self-renewal, multi-potency and tumor-initiation, may consist of 
subgroups of cells that express different phenotypic markers and exhibit different 
functional characteristics. CD133 is thus far the best-characterized marker for 
cancer stem cells, although it may identify only one subgroup of cancer stem 
cells. Whether other subgroups within the cancer stem cell population respond to 
Hh pathway inhibition is uncertain at this point. Also unknown is the possibility 
that CD133+ cells are themselves progeny of these multi-potent subgroups. This 
raises the possibility that the incomplete tumor regression and eventual death of 
our cyclopamine treated mice may depend upon the inability of Hh pathway 
inhibition to block the growth of these other cell types. Discovering unique 
markers that can identify these various cell types can help us define more 
accurately the hierarchy that governs CD133+ cells. 
In our studies, we demonstrated that the Hh pathway can be inhibited in 
vivo and leads to significant survival advantage only in treated mice bearing Hh-
responsive tumors. Taken together, the results of our studies do not support the 
“one size fits all” hypothesis for the role of Hedgehog signaling in gliomas 
purported in previous reports. Our hope is that rigorous design of clinical trials 
based on Hedgehog pathway inhibitors will take into account this significant 
distinction. 
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